<Bundle xmlns="http://hl7.org/fhir"><id value="d4a3f6bd-7e32-431a-a16c-7ac4bc81139e" /><identifier><system value="http://ema.europa.eu/fhir/epiGuid" /><value value="d4a3f6bd-7e32-431a-a16c-7ac4bc81139e" /></identifier><type value="collection" /><timestamp value="2024-12-04T17:54:30.5616178+01:00" /><entry><fullUrl value="85904983-aecc-44ad-a1eb-92d44b64724f" /><resource><List><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) master document list</div></text><identifier><system value="http://ema.europa.eu/fhir/epiId" /><value value="EPI/24/129" /></identifier><status value="current" /><mode value="working" /><title value="all sections Spanish document" /><code><coding><system value="http://ema.europa.eu/fhir/documentType" /><code value="00001" /><display value="epiMasterList" /></coding></code><subject><reference value="subjectReference" /></subject><entry><item><reference value="referenceToDocument" /><display value="Ficha técnica o resumen de las características del producto" /></item></entry><entry><item><reference value="referenceToDocument" /><display value="Prospecto" /></item></entry></List></resource></entry><entry><fullUrl value="2d67ad1b-6fa0-4bf7-a4ae-023c33bbb336" /><resource><Bundle><id value="2d67ad1b-6fa0-4bf7-a4ae-023c33bbb336" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="2d67ad1b-6fa0-4bf7-a4ae-023c33bbb336" /></identifier><type value="document" /><timestamp value="2024-12-04T17:54:30.5616178+01:00" /><entry><fullUrl value="2d67ad1b-6fa0-4bf7-a4ae-023c33bbb336" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155532" /><display value="Ficha técnica o resumen de las características del producto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-04" /><author><reference value="systemUser" /></author><title value="Ficha técnica o resumen de las características del producto" /><section><title value="Ficha técnica o resumen de las características del producto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029791" /><display value="Ficha técnica o resumen de las características del producto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="ab9d439a-3ee4-4462-b458-fc3b28792fb8"><title value="0. Advertencia triángulo negro" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="Advertencia triángulo negro" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><img src="data:image/jpg;base64,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" width="23" height="19" alt="BT_1000x858px" /><span style="font-family:Times New Roman; font-size:11pt">Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas. Ver la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8, en la que se incluye información sobre cómo notificarlas.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="c70f801f-6af4-43e4-9c54-21a1257f92b6"><title value="1. Nombre del medicamento" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029792" /><display value="Nombre del medicamento" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey 200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/</span><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg</span><span style="font-family:Times New Roman; font-size:11pt">comprimidos recubiertos con película.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="6f3f6238-0559-497f-8e13-0009b1dd6267"><title value="2. Composición cualitativa y cuantitativa" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029793" /><display value="Composición cualitativa y cuantitativa" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Cada comprimido recubierto con película contiene 200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de emtricitabina, rilpivirina hidrocloruro equivalente a 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de rilpivirina y tenofovir alafenamida fumarato equivalente a 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de tenofovir alafenamida.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Excipientes con efecto conocido</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Cada comprimido contiene 189,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de lactosa monohidrato.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Para consultar la lista completa de excipientes, ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6.1.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="5a2b02db-201e-42d8-ad12-26503af6aff0"><title value="3. Forma farmacéutica" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029797" /><display value="Forma farmacéutica" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Comprimido recubierto con película.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Comprimidos recubiertos con película, de color gris, en forma de cápsula, de dimensiones 15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mm</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">x</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mm, marcados en una de las caras del comprimido con “GSI” y en la otra cara del comprimido con “255”.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="062cc008-fce0-4819-a74e-2bc1387f5a69"><title value="4. Datos clínicos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029798" /><display value="Datos clínicos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="8fa284d2-e89c-47c9-8f02-93eccc61c182"><title value="4.1. Indicaciones terapéuticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029799" /><display value="Indicaciones terapéuticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey está indicado para el tratamiento de adultos y adolescentes (de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad o mayores con un peso corporal de al menos 35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg) infectados con el virus de la inmunodeficiencia humana tipo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 (VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1) sin mutaciones conocidas asociadas con resistencia a los inhibidores de la transcriptasa inversa no análogos de nucleósidos (ITINN), tenofovir o emtricitabina y con una carga viral de ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2, 4.4 y 5.1).</span></p></div></text></section><section id="7cf20958-4a40-453b-8789-e60b5f652d0a"><title value="4.2. Posología y forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029800" /><display value="Posología y forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El tratamiento se debe iniciar por un médico con experiencia en el tratamiento de la infección por el</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">VIH.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text><section id="f255544a-31fe-495d-b79b-9d2c2df45a8a"><title value="4.2.1. Posología" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029801" /><display value="Posología" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Adultos y adolescentes de 12</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">años de edad o mayores con un peso de al menos 35</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">kg</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Un comprimido que se debe tomar una vez al día con alimentos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si el paciente omite una dosis de Odefsey en el plazo de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas desde la hora normal de administración, debe tomar Odefsey lo antes posible con alimentos y continuar la pauta habitual de administración. Si el paciente omite una dosis de Odefsey durante más de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas, no debe tomar la dosis omitida y simplemente debe continuar la pauta habitual de administración.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si el paciente vomita en el plazo de 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de tomar Odefsey, debe tomar otro comprimido con alimentos. Si el paciente vomita más de 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de tomar Odefsey, no necesita tomar otra dosis de Odefsey hasta la próxima dosis habitual programada.</span><br /></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes de edad avanzada</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se requiere un ajuste de la dosis de Odefsey en pacientes de edad avanzada (ver</span><span style="font-family:Times New Roman; font-size:11pt">sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2).</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se requiere un ajuste de la dosis de Odefsey en adultos o en adolescentes (de al menos 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad y al menos 35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg de peso corporal) con un aclaramiento de creatinina estimado (</span><a name="_Hlk6894507"><span style="font-family:Times New Roman; font-size:11pt">ClCr</span></a><span style="font-family:Times New Roman; font-size:11pt">) ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min. Odefsey se debe suspender en los pacientes cuyo ClCr estimado descienda por debajo de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min durante el tratamiento (ver sección 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se requiere un ajuste de la dosis de Odefsey en</span><span style="font-family:Times New Roman; font-size:11pt">adultos con nefropatía terminal (ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) en hemodiálisis crónica</span><span style="font-family:Times New Roman; font-size:11pt">; aunque en general Odefsey se debe evitar, se puede utilizar con precaución en estos pacientes si se considera que los posibles beneficios superan a los posibles riesgos (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4 y 5.2). En los días de hemodiálisis, Odefsey se debe administrar cuando esta haya finalizado.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey se debe evitar en pacientes con ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min, o &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min que no reciben hemodiálisis crónica, ya que no se ha establecido la seguridad de Odefsey en estas poblaciones.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se dispone de datos que permitan hacer recomen</span><span style="font-family:Times New Roman; font-size:11pt">daciones sobre la dosis en menores de 18 años con nefropatía terminal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia hepática</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se requiere un ajuste de la dosis de Odefsey en pacientes con insuficiencia hepática leve (clase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">A de Child</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Pugh) o moderada (clase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B de Child</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Pugh). Odefsey se debe utilizar con precaución en pacientes con insuficiencia hepática moderada. No se ha estudiado Odefsey en pacientes con insuficiencia hepática grave (clase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C de Child</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Pugh)</span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">,</span></span><span style="font-family:Times New Roman; font-size:11pt">por tanto, no se recomienda el uso de Odefsey en pacientes con insuficiencia hepática grave (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4 y 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se ha establecido todavía la seguridad y eficacia de Odefsey en niños menores de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad o que pesen &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg. No se dispone de datos.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Durante el embarazo se observaron exposiciones inferiores de rilpivirina (uno de los componentes de Odefsey), por lo que se debe realizar un seguimiento estrecho de la carga viral. De forma alternativa, se puede considerar cambiar a otra pauta de tratamiento antirretroviral (ver las secciones 4.4, 4.6, 5.1 y 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="b94a7f02-95eb-4928-aa99-6ff778f0339c"><title value="4.2.2. Forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029803" /><display value="Forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey se debe tomar por vía oral, una vez al día con alimentos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2). El comprimido recubierto con película no se debe masticar, machacar ni partir.</span></p></div></text></section></section><section id="385aefda-57e9-41c9-8a71-49b7ca69c2d2"><title value="4.3. Contraindicaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029805" /><display value="Contraindicaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Hipersensibilidad a los principios activos o a alguno de los excipientes incluidos en la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6.1.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey no se debe administrar de forma concomitante con medicamentos que puedan causar disminuciones significativas de las concentraciones plasmáticas de rilpivirina (debido a la inducción enzimática del citocromo P450 [CYP]3A o al aumento del pH gástrico), lo que puede dar como resultado la pérdida del efecto terapéutico de Odefsey (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5), entre ellos:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt" ><li style="margin:0pt 0pt 0pt 17.16pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">carbamazepina, oxcarbazepina, fenobarbital, fenitoína</span></li><li style="margin:0pt 0pt 0pt 17.16pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rifabutina, rifampicina, rifapentina</span></li><li style="margin:0pt 0pt 0pt 17.16pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">omeprazol, esomeprazol, dexlansoprazol, lansoprazol, pantoprazol, rabeprazol</span></li><li style="margin:0pt 0pt 0pt 17.16pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dexametasona (dosis por vía oral o parenteral), excepto como tratamiento de dosis única</span></li><li style="margin:0pt 0pt 0pt 17.16pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hierba de San Juan (</span><em><span style="font-family:Times New Roman; font-size:11pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul></div></text></section><section id="58a5a2a4-8f54-4930-8450-849be3785c0e"><title value="4.4. Advertencias y precauciones especiales de empleo" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029806" /><display value="Advertencias y precauciones especiales de empleo" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">A pesar de que se ha comprobado que una supresión viral eficaz con un tratamiento antirretroviral reduce sustancialmente el riesgo de transmisión sexual, no se puede excluir un riesgo residual. Se deben tomar precauciones, conforme a las directrices nacionales, para prevenir la transmisión.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Fracaso virológico y aparición de resistencias</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No hay datos suficientes para justificar el uso en pacientes con fracaso previo con ITINN. La realización de pruebas de resistencia y/o los antecedentes de resistencias deben guiar el uso de Odefsey (ver sección 5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el análisis combinado de eficacia de los dos estudios clínicos de fase III en adultos (C209 [ECHO] y C215 [THRIVE]) durante 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, los pacientes tratados con emtricitabina/tenofovir disoproxilo fumarato</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">rilpivirina con una carga viral basal de ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml tuvieron un mayor riesgo de fracaso virológico (17,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con rilpivirina frente a 7,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con efavirenz) en comparación con los pacientes con una carga viral basal de ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (5,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con rilpivirina frente a</span><span style="font-family:Times New Roman; font-size:11pt">2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con efavirenz). La tasa de fracaso virológico en los pacientes tratados con emtricitabina/tenofovir disoproxilo fumarato</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">rilpivirina en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 fue del 9,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y el 11,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, respe</span><span style="font-family:Times New Roman; font-size:11pt">ctivamente, y del 4,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y el 5,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% en el grupo de emtricitabina/tenofovir disoproxilo fumarato + efavirenz. La diferencia en la tasa de nuevos fracasos virológicos desde la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 a la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 entre los grupos de rilpivirina y efavirenz no fue estadísticamente significativa. Los pacientes con una carga viral basal de ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml que presentaron fracaso virológico mostraron una mayor tasa de resistencia emergente al tratamiento para los ITINN. Más pacientes que habían fracasado virológicamente con rilpivirina que los que habían fracasado virológicamente con efavirenz desarrollaron resistencia asociada a lamivudina/emtricitabina (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los hallazgos en los adolescentes (de 12 a menos de 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad) en el estudio C213 estuvieron generalmente en consonancia con estos datos (para más detalles, ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Sólo los adolescentes más propensos a tener un buen cumplimiento de la terapia antirretroviral deben ser tratados con rilpivirina, ya que un cumplimiento subóptimo puede conducir al desarrollo de resistencias y a la pérdida de opciones de tratamiento en el futuro.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedades cardiovasculares</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">A dosis supraterapéuticas (75</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y 300</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día), se ha asociado a rilpivirina con la prolongación del intervalo QTc del electrocardiograma (ECG) (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5 y 4.9). Rilpivirina a la dosis recomendada de 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día no está asociada a un efecto clínicamente relevante sobre el QTc. Odefsey se debe utilizar con precaución cuando se administre de forma concomitante con medicamentos con un riesgo conocido de Torsade de Pointes.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Pacientes coinfectados por el VIH y el virus de la hepatitis</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">B o</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">C</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes con hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C crónica, tratados con terapia antirretroviral tienen un riesgo mayor de padecer reacciones adversas hepáticas graves y potencialmente mortales.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha establecido la seguridad y eficacia de Odefsey en pacientes coinfectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 y el virus de la hepatitis C (VHC).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida es activo frente al virus de la hepatitis B (VHB). La interrupción del tratamiento con Odefsey en pacientes coinfectados por VIH y VHB puede estar asociada con exacerbaciones agudas graves de la hepatitis. En pacientes coinfectados por VIH y VHB que interrumpen el tratamiento con Odefsey hay que realizar un seguimiento estrecho, clínico y de laboratorio, durante al menos varios meses después de suspender el tratamiento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad hepática</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha establecido la seguridad y eficacia de Odefsey en pacientes con trastornos hepáticos significativos subyacentes.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes con insuficiencia hepática preexistente, incluida hepatitis crónica activa, tienen una frecuencia mayor de alteraciones de la función hepática durante la terapia antirretroviral combinada (TARC) y se deben monitorizar de acuerdo con las prácticas habituales. Si hay evidencia de empeoramiento de la enfermedad hepática en dichos pacientes, se debe considerar la interrupción o suspensión del tratamiento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Peso y parámetros metabólicos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Durante el tratamiento antirretroviral se puede producir un aumento en el peso y en los niveles de glucosa y lípidos en la sangre. Tales cambios pueden estar relacionados en parte con el control de la enfermedad y en parte con el estilo de vida. Para los lípidos, hay en algunos casos evidencia de un efecto del tratamiento, mientras que para la ganancia de peso no hay una evidencia sólida que relacione esto con un tratamiento en particular. Para monitorizar los niveles de lípidos y de glucosa en la sangre, se hace referencia a pautas establecidas en las guías de tratamiento del VIH. Los trastornos lipídicos se deben tratar como se considere clínicamente apropiado.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Disfunción mitocondrial tras la exposición</span></span><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">in</span></span></em><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span></em><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">utero</span></span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los análogos de nucleósidos o nucleótidos pueden afectar a la función mitocondrial en grados variables, lo cual es más pronunciado con estavudina, didanosina y zidovudina. Existen informes de disfunción mitocondrial en lactantes VIH negativo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">expuestos</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">utero</span></em><span style="font-family:Times New Roman; font-size:11pt">y/o posparto a análogos de nucleósidos; predominantemente esto ha afectado al tratamiento con pautas de tratamiento que contienen zidovudina. Las principales reacciones adversas notificadas son trastornos hematológicos (anemia, neutropenia) y trastornos metabólicos (hiperlactacidemia, hiperlipasemia). Estas reacciones son a menudo transitorias. Se han notificado de forma rara trastornos neurológicos de aparición tardía (hipertonía, convulsión, comportamiento anormal). Actualmente no se sabe si dichos trastornos neurológicos son transitorios o permanentes. Estos hallazgos se deben tener en cuenta para cualquier niño expuesto</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">utero</span></em><span style="font-family:Times New Roman; font-size:11pt">a análogos de nucleósidos o nucleótidos que presente hallazgos clínicos graves de etiología desconocida, particularmente hallazgos neurológicos. Estos hallazgos no afectan a las recomendaciones nacionales actuales para utilizar tratamiento antirretroviral en mujeres embarazadas para prevenir la transmisión vertical del VIH.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Síndrome de reconstitución inmunitaria</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Cuando se instaura una TARC en pacientes infectados por VIH con deficiencia inmunitaria grave puede aparecer una respuesta inflamatoria frente a patógenos oportunistas latentes o asintomáticos y provocar situaciones clínicas graves, o un empeoramiento de los síntomas. Normalmente estas reacciones se han observado en las primeras semanas o meses después del inicio de la TARC. Algunos ejemplos relevantes de estas reacciones incluyen: retinitis por citomegalovirus, infecciones micobacterianas generalizadas y/o localizadas y neumonía por</span><em><span style="font-family:Times New Roman; font-size:11pt;">Pneumocystis jirovecii</span></em><span style="font-family:Times New Roman; font-size:11pt">. Se debe evaluar cualquier síntoma inflamatorio y establecer un tratamiento cuando sea necesario.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado también trastornos autoinmunitarios (como la enfermedad de Graves y la hepatitis autoinmune) en caso de reconstitución inmunitaria; no obstante, el tiempo hasta el inicio notificado es más variable y estos acontecimientos se pueden producir varios meses después del inicio del tratamiento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Infecciones oportunistas</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que reciban Odefsey pueden continuar adquiriendo infecciones oportunistas y otras complicaciones de la infección por el VIH y deben permanecer, por lo tanto, bajo la observación clínica estrecha de médicos expertos en el tratamiento de pacientes con enfermedades asociadas al</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">VIH.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Osteonecrosis</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado casos de osteonecrosis, especialmente en pacientes con infección avanzada por VIH y/o exposición prolongada a la TARC, aunque se considera que la etiología es multifactorial (incluyendo uso de corticosteroides, consumo de alcohol, inmunodepresión grave, índice de masa corporal elevado). Se debe aconsejar a los pacientes que consulten al médico si experimentan molestias o dolor articular, rigidez articular o dificultad para moverse.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Nefrotoxicidad</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No se puede excluir un posible riesgo de nefrotoxicidad resultante de la exposición crónica a niveles bajos de tenofovir debida a la administración de tenofovir alafenamida (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.3).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Pacientes con nefropatía terminal que reciben hemodiálisis crónica</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En general, Odefsey se debe evitar pero se puede utilizar con precaución en adultos con nefropatía terminal (ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15 ml/min) que reciben hemodiálisis crónica si los posibles beneficios superan a los posibles riesgos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2). En un estudio de emtricitabina + tenofovir alafenamida en combinación con elvitegravir + cobicistat en un comprimido de combinación a dosis fija (E/C/F/TAF) en adultos infectados por el VIH-1 con nefropatía terminal (ClCr</span><span style="font-family:Times New Roman; font-size:11pt">estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15 ml/min) en hemodiálisis crónica, la eficacia se mantuvo durante 48 semanas, pero la exposición a emtricitabina fue significativamente superior a la obtenida en pacientes con función renal normal. Aunque no se identificaron problemas de seguridad nuevos, las consecuencias del aumento de la exposición a emtricitabina continúan siendo inciertas (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8 y 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron exposiciones inferiores de rilpivirina cuando se administró 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día de rilpivirina durante el embarazo. En los estudios de fase III (C209 y C215), una exposición inferior de rilpivirina, similar a la observada durante el embarazo, se ha asociado con un aumento del riesgo de fracaso virológico; por lo que se debe realizar un seguimiento estrecho de la carga viral (ver las secciones 4.6, 5.1 y 5.2). De forma alternativa, se puede considerar cambiar a otra pauta de tratamiento antirretroviral.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Administración concomitante de otros medicamentos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Algunos medicamentos no se deben administrar de forma concomitante con Odefsey (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.3 y 4.5).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey no se debe administrar de forma concomitante con otros medicamentos antirretrovirales (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey no se debe administrar de forma concomitante con otros medicamentos que contengan tenofovir alafenamida, lamivudina, tenofovir disoproxilo o adefovir dipivoxil (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Excipientes</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey contiene lactosa monohidrato. Los pacientes con intolerancia hereditaria a galactosa, deficiencia total de lactasa o problemas de absorción de glucosa o galactosa no deben tomar este medicamento.</span></p></div></text></section><section id="40628e01-6711-469d-b58f-97f111ee552e"><title value="4.5. Interacción con otros medicamentos y otras formas de interacción" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029809" /><display value="Interacción con otros medicamentos y otras formas de interacción" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey está indicado para su uso como pauta completa para el tratamiento de la infección por VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 y no se debe administrar de forma concomitante con otros medicamentos antirretrovirales. Por lo tanto, no se facilita información sobre interacciones medicamentosas con otros antirretrovirales. Los estudios de interacciones se han realizado sólo en adultos.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Emtricitabina</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los estudios de interacciones medicamentosas farmacocinéticas clínicos e</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">han mostrado que el potencial de interacciones mediadas por el CYP entre emtricitabina y otros medicamentos es bajo. La administración concomitante de emtricitabina con medicamentos que se eliminan mediante secreción tubular activa puede aumentar las concentraciones de emtricitabina y/o del medicamento administrado de forma concomitante. Los medicamentos que reducen la función renal pueden aumentar las concentraciones de emtricitabina.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Rilpivirina</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina se metaboliza principalmente a través de CYP3A. Los medicamentos que inducen o inhiben CYP3A pueden, por tanto, afectar al aclaramiento de rilpivirina (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2). Rilpivirina inhibe la glicoproteína P (P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp)</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">(la concentración inhibitoria del 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% [CI</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">] es 9,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µM). En un estudio clínico, rilpivirina no afectó significativamente a la farmacocinética de la digoxina. Además, en un estudio clínico de interacciones medicamentosas con tenofovir alafenamida, que es más sensible a la inhibición intestinal de la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp, rilpivirina no afectó a las exposiciones de tenofovir alafenamida cuando se administraron simultáneamente, indicando que rilpivirina no es un inhibidor de la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina es un inhibidor</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">del transportador MATE</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2K, con una CI</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">de &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM. Las implicaciones clínicas de este hallazgo se desconocen en la actualidad.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tenofovir alafenamida</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida se transporta por la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp y la proteína de resistencia de cáncer de mama (BCRP, por sus siglas en inglés). Los medicamentos que afectan a la actividad de la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp y BCRP pueden producir cambios en la absorción de tenofovir alafenamida (ver Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1). Se prevé que los medicamentos que inducen la actividad de la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp (p. ej., rifampicina, rifabutina, carbamazepina, fenobarbital) reduzcan la absorción de tenofovir alafenamida, dando lugar a una concentración plasmática reducida de tenofovir alafenamida, lo que puede redundar en una pérdida del efecto terapéutico de Odefsey y la aparición de resistencias. Se prevé que la administración concomitante de Odefsey con otros medicamentos que inhiben la actividad de la P</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">gp y de la BCRP (p. ej., ketoconazol, fluconazol, itraconazol, posaconazol, voriconazol, ciclosporina) aumente la absorción y la concentración plasmática de tenofovir alafenamida. A partir de los datos procedentes de un estudio</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">, no se espera que la administración concomitante de tenofovir alafenamida con inhibidores de la xantina oxidasa (p. ej. febuxostat) aumente la exposición sistémica a tenofovir</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida no es un inhibidor de CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 o CYP2D6</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">. Tenofovir alafenamida no es un inhibidor ni un inductor de CYP3A</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vivo.</span></em><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida es un sustrato del polipéptido transportador de aniones orgánicos (OATP)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1B1 y de OATP1B3</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">. La distribución de tenofovir alafenamida en el organismo se puede ver afectada por la actividad de OATP1B1 y de OATP1B3.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uso concomitante contraindicado</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se ha observado que la administración concomitante de Odefsey y medicamentos que inducen CYP3A disminuye las concentraciones plasmáticas de rilpivirina, lo que potencialmente podría conducir a la pérdida de respuesta virológica a Odefsey (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.3) y a la posible resistencia a rilpivirina y los ITINN.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se ha observado que la administración concomitante de Odefsey e inhibidores de la bomba de protones disminuye las concentraciones plasmáticas de rilpivirina (debido al aumento del pH gástrico), lo que potencialmente podría conducir a la pérdida de respuesta virológica a Odefsey (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.3) y a la posible resistencia a rilpivirina y los ITINN.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uso concomitante para el cual se recomienda precaución</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores de las enzimas</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">CYP</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se ha observado que la administración concomitante de Odefsey y medicamentos que inhiben la actividad de la enzima CYP3A aumenta las concentraciones plasmáticas de rilpivirina.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos que producen prolongación de QT</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey se debe utilizar con precaución cuando se administra junto con un medicamento asociado a un riesgo conocido de Torsade de Pointes (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Otras interacciones</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida no es un inhibidor de la uridina difosfato glucuronosiltransferasa (UGT)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1A1 humana</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro.</span></em><span style="font-family:Times New Roman; font-size:11pt">No se sabe si emtricitabina o tenofovir alafenamida son inhibidores de otras enzimas UGT. Emtricitabina no inhibió la reacción de glucuronidación de un sustrato UGT no específico</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Las interacciones entre Odefsey o sus componentes ind</span><span style="font-family:Times New Roman; font-size:11pt">ividuales y los medicamentos administrados de forma concomitante se enumeran a continuación en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 (el aumento está indicado como “↑”, la disminución, como “↓”, la ausencia de cambios, como “↔”).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1:</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">Interacciones entre Odefsey o sus component</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">es individuales</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">y otros medicamentos</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Medicamento por áreas terapéuticas</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Efectos sobre las concentraciones de</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">medicamento.</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Cambio porcentual medio en AUC, C</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">, C</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Recomendación relativa a la administración concomitante con Odefsey</span></strong></p></td></tr></thead><tbody><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTIINFECCIOSOS</span></em></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Antifúngicos</span></strong></p></td></tr><tr style="height:92.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ketoconazol (400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ketoconazol:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 24</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 66</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 49</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 76</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 30</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inhibición de CYP3A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Previsto:</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tenofovir alafenamida:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inhibición de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con tenofovir alafenamida. Se prevé que la administrac</span><span style="font-family:Times New Roman; font-size:10pt">ión concomitante de ketoconazol aumente las concentraciones plasmáticas de tenofovir alafenamida (inhibición de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se recomienda la administración concomitante.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Fluconazol</span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Itraconazol</span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Posaconazol</span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Voriconazol</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. Se prevé que la administración concomitante de estos antifúngicos aumente las concentraciones plasmáticas de rilpivirina (inhibición de CYP3A) y tenofovir alafenamida (inhibición de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:dashed; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se recomienda la administraci</span><span style="font-family:Times New Roman; font-size:10pt">ón concomitante.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Antimicobacterianos</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifampicina/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifampicina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">25</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">desacetil</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">rifampicina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 80</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 89</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 69</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inducción de CYP3A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Previsto:</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tenofovir alafena</span><span style="font-family:Times New Roman; font-size:10pt">mida:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con tenofovir alafenamida. Es probable que la administración concomitante cause disminuciones significativas de las concentraciones plasmáticas de tenofovir alafenamida (inducción de la</span><span style="font-family:Times New Roman; font-size:10pt">P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifapentina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. Es probable que la administración concomitante cause disminuciones significativas de las concentraciones plasmáticas de rilpivirina (inducción de CYP3A) y tenofovir alafenamida (inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifabutina (300</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifabutina (300</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rifabutina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">25</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">O</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">desacetil</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">rifabutina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 42</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 48</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 31</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inducción de CYP3A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Previsto:</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tenofovir alafenamida:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con tenofovir</span><span style="font-family:Times New Roman; font-size:10pt">alafenamida. La administración concomitante es probable que cause disminuciones significativas de las concentraciones plasmáticas de tenofovir alafenamida (inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Antibióticos macrólidos</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Claritromicina</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Eritromicina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. La combinación de Odefsey con estos antibióticos macrólidos puede causar un aumento de las concentraciones plasmáticas de rilpivirina (inhibición de CYP3A)</span><span style="font-family:Times New Roman; font-size:10pt">y tenofovir alafenamida (inhibición de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se recomienda la administración concomitante.</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Fármacos antivirales</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ledipasvir/Sofosbuvir (90</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ledipasvir:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metabolito de sofosbuvir GS</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">331007:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 10</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:dashed; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ledipasvir/Sofosbuvir (90</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Tenofovir alafenamida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:dashed; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tenofovir al</span><span style="font-family:Times New Roman; font-size:10pt">afenamida:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 32</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir/Velpatasvir</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(400 mg/100 mg una vez al día)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metabolito de sofosbuvir GS-331007:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Velpatasvir:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#c0c0c0; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir/Velpatasvir/Voxilaprevir</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/100</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/100</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">+</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:10pt">/ Emtricitabina/Rilpivirina/Tenofovir alafenamida (200</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg/25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Met</span><span style="font-family:Times New Roman; font-size:10pt">abolito de sofosbuvir GS-331007:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Velpatasvir:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Voxilaprevir:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Emtricitabina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tenofovir alafenamida:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 52%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">m</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">ax</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 32%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir (400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina (25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sofosbuvir:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">21</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metabolito de sofosbuvir GS</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">331007:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajus</span><span style="font-family:Times New Roman; font-size:10pt">tar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">Simeprevir (150 mg una vez al</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">día)/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">Simeprevir:</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">AUC: ↑ 6 %</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">C</span><span style="font-family:TimesNewRomanPSMT; font-size:6.5pt">min</span><span style="font-family:TimesNewRomanPSMT; font-size:10pt">: ↓ 4 %</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">C</span><span style="font-family:TimesNewRomanPSMT; font-size:6.5pt">max</span><span style="font-family:TimesNewRomanPSMT; font-size:10pt">: ↑ 10 %</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt"> </span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">AUC: ↑ 12 %</span></p><p style="margin:0pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">C</span><span style="font-family:TimesNewRomanPSMT; font-size:6.5pt">min</span><span style="font-family:TimesNewRomanPSMT; font-size:10pt">: ↑ 25 %</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:TimesNewRomanPSMT; font-size:10pt">C</span><span style="font-family:TimesNewRomanPSMT; font-size:6.5pt">max</span><span style="font-family:TimesNewRomanPSMT; font-size:10pt">: ↑ 4 %</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTIEPILÉPTICOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Carbamazepina</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Oxcarbazepina</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Fenobarbital</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Fe</span><span style="font-family:Times New Roman; font-size:10pt">nitoína</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. La administración concomitante puede causar disminuciones significativas de las concentraciones plasmáticas de rilpivirina (inducción de CYP3A) y tenofovir alafenamida (inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">GLUCOCORTICOIDES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Dexametasona (sistémica, excepto para uso en dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. Se esperan disminuciones significativas de las</span><span style="font-family:Times New Roman; font-size:10pt">concentraciones plasmáticas de rilpivirina dependientes de la dosis (inducción de CYP3A).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">INHIBIDORES DE LA BOMBA DE PROTONES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Omeprazol (20</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Omeprazol:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 14</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">:</span><span style="font-family:Times New Roman; font-size:10pt">N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 14</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 33</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Menor absorción, aumento del pH gástrico</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Lansoprazol</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rabeprazol</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Pantoprazol</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Esomeprazol</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Dexlansoprazol</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con</span><span style="font-family:Times New Roman; font-size:10pt">ninguno de los componentes de Odefsey. Se esperan disminuciones significativas de las concentraciones plasmáticas de rilpivirina (disminución de la absorción, aumento del pH gástrico).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">MEDICAMENTOS A BASE DE PLANTAS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Hierba de San Juan (</span><em><span style="font-family:Times New Roman; font-size:10pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. La administración concomitante puede causar disminuciones significativas de las concentraciones plasmáticas de rilpivirina (inducción de CYP3A) y tenofovir alafenamida (inducción de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">La administración concomitante está contraindicada</span><span style="font-family:Times New Roman; font-size:10pt">.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTAGONISTAS DE LOS RECEPTORES H</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">2</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:dashed; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Famotidina (40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única tomada 12 horas antes de rilpivirina)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Famotidina (40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única tomada 2 horas antes de rilpivirina)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Famotidina (40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única tomada 4 horas después de rilpivirina)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:dashed; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 76</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 85</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Menor absorción, aumento del pH gástrico</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 13</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 21</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sólo se deben utilizar los antagonistas de los receptores H</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:10pt">que puedan administrarse un</span><span style="font-family:Times New Roman; font-size:10pt">a vez al día. Se debe utilizar una estricta pauta de dosificación, con ingesta de los antagonistas de los receptores H</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:10pt">al menos 12</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">horas después de Odefsey.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:dashed; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Cimetidina</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Nizatidina</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ranitidina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:dashed; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. La administración concomitante puede causar disminuciones significativas de las concentraciones plasmáticas de rilpivirina (disminución de la absorción, aumento del pH gástrico).</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTIÁCIDOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Antiácidos (p. ej., hidróxido de aluminio o magnesio, carbonato de calcio)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. La administración concomitante puede causar disminuciones significativas de las concentraciones plasmáticas de rilpivirina (disminución de la absorción, aumento del pH gástrico).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Los antiácidos sólo se deben administrar o bien al menos 2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">horas después de Odefsey.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTICONCEPTIVOS ORALES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Etinilestradiol (0,035</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Noretindrona (1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">día)/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Etinilestradiol:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 17</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Noretindrona:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">*basado en controles históricos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Norgestimato (0,180</span><span style="font-family:Times New Roman; font-size:10pt">/0,215/0,250</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Etinilestradiol (0,025</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Emtricitabina/Tenofovir alafenamida (200/25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Norelgestromina:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Norgestrel:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Etinilestradiol:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No</span><span style="font-family:Times New Roman; font-size:10pt">es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANALGÉSICOS NARCÓTICOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metadona (60</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">100</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día, dosis individualizada)/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">R(-) metadona:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 16</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 22</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 14</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">S(+) metadona:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↓ 16</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 21</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 13</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔*</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">*basado en controles históricos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se requieren ajustes de dosis.</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Se recomienda realizar una monitorización clínica ya que puede ser necesario ajustar la terapia de mantenimiento con metadona en algunos pacientes.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANALGÉSICOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Paraceta</span><span style="font-family:Times New Roman; font-size:10pt">mol (500</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Paracetamol:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC:</span><span style="font-family:Times New Roman; font-size:10pt">↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">:</span><span style="font-family:Times New Roman; font-size:10pt">↑ 26</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">:</span><span style="font-family:Times New Roman; font-size:10pt">↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTIARRÍTMICOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Digoxina/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Digoxina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosi</span><span style="font-family:Times New Roman; font-size:10pt">s.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTICOAGULANTES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Dabigatrán etexilato</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se puede excluir un riesgo de aumentos de las concentraciones plasmáticas de dabigatrán (inhibición intestinal de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">La administración</span><span style="font-family:Times New Roman; font-size:10pt">concomitante debe utilizarse con precaución</span><span style="font-family:Times New Roman; font-size:10pt">.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">INMUNOSUPRESORES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ciclosporina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. Se prevé que la administración concomitante de ciclosporina aumente las concentraciones plasmáticas de rilpiviri</span><span style="font-family:Times New Roman; font-size:10pt">na (inhibición de CYP3A) y tenofovir alafenamida (inhibición de la P</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">gp).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No se recomienda la administración concomitante.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">ANTIDIABÉTICOS</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metformina (850</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única)/Rilpivirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Metformina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">INHIBIDORES DE LA HMG</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">CO</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">‑</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">A REDUCTASA</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Atorvastatina (40</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg una vez al día)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Atorvastatina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↓</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">15</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">35</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">FDE</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">‑</span></em></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">5)</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sildenafilo (50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dosis única)/Rilpivirina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sildenafilo:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Rilpivirina:</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↔</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Vardenafilo</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Tadalafilo</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interacción no estudiada con ninguno de los componentes de Odefsey. So</span><span style="font-family:Times New Roman; font-size:10pt">n medicamentos pertenecientes a la misma clase por lo que se podrían predecir interacciones similares.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">HIPNÓTICOS/SEDANTES</span></em></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Midazolam (2,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg por vía oral, dosis única)/Tenofovir alafenamida</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Midazolam (1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg por vía intravenosa, dosis única)/Tenofovir alafenamida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:37.54%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Midazolam:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 12</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↑ 2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Midazolam:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">AUC: ↑ 8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">min</span><span style="font-family:Times New Roman; font-size:10pt">: N/A</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">: ↓ 1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:28.56%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">No es necesario ajustar la dosis.</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:157.45pt; border:none">
                                        </td>
                                        <td style="width:158.85pt; border:none">
                                        </td>
                                        <td style="width:119.7pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt; background-color:#ffffff" ><span style="font-family:Times New Roman; font-size:9pt">N/A</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">no aplicable</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt; background-color:#ffffff" ><span style="font-family:Times New Roman; font-size:9pt">1</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Este estudio de interacciones ha sido realizado con una dosis superior a la dosis recomendada de rilpivirina hidrocloruro</span><span style="font-family:Times New Roman; font-size:9pt">para evaluar el efecto máximo sobre el medicamento administrado de forma concomitante. La recomendación de administración es aplicable a la dosis recomendada de rilpivirina de 25</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">mg una vez al día.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">2</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">             </span><span style="font-family:Times New Roman; font-size:9pt">Estudio realizado con el comprimido de combinación de dosis fija de emtricitabina/rilpivirina/tenofovir disoproxilo fumarato.</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">3</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Estudio realizado con 100</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">mg adicionales de voxilaprevir para obtener las exposiciones a voxilaprevir esperadas en pacientes infectados por el VHC.</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Estudios realizados con otros medicamentos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Basándonos en los estudios de interacciones medicamentosas realizados con los componentes de Odefsey, no se esperan interacciones clínicamente significativas cuando Odefsey se combina con los siguientes medicamentos: buprenorfina, naloxona y norbuprenorfina.</span></p></div></text></section><section id="5779723b-108f-425e-838c-e81ede3154ce"><title value="4.6. Fertilidad, embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029811" /><display value="Fertilidad, embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mujeres en edad fértil/anticoncepción en hombres y mujeres</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">El uso de Odefsey se debe acompañar del empleo de métodos anticonceptivos efectivos.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No hay estudios adecuados y bien controlados de Odefsey o de sus componentes en mujeres embarazadas.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt">Los datos (datos en menos de 300 embarazos) relativos al uso de rilpivirina y tenofovir alafenamida en mujeres embarazadas son limitados (ver las secciones 4.4, 5.1 y 5.2). Durante el embarazo se observaron exposiciones inferiores de rilpivirina; por lo que se debe realizar un seguimiento estrecho de la carga viral. Existe un elevado número de datos en mujeres embarazadas (datos en más de 1.000 embarazos expuestos) que indican que emtricitabina no produce malformaciones ni toxicidad fetal/neonatal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los estudios en animales no sugieren efectos perjudiciales directos ni indirectos en términos de toxicidad para la reproducción con los componentes de Odefsey (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.3).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt">Como medida de precaución, es preferible evitar el uso de Odefsey .durante el embarazo</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Lactancia</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Emtricitabina se excreta en la leche materna.</span><span style="font-family:Times New Roman; font-size:11pt">Se desconoce si rilpivirina o tenofovir alafenamida se excretan en la leche materna. En estudios en animales se ha observado que tenofovir se excreta en la</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">leche.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt">No hay datos suficientes sobre los efectos de todos los componentes de Odefsey en recién nacidos/lactantes, por lo tanto Odefsey no se debe utilizar durante la lactancia.</span></p><p style="margin:0pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt">Para evitar la transmisión del VIH al lactante, se recomienda que las mujeres que presentan infección por VIH no den el pecho a sus hijos bajo ningún concepto.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Fertilidad</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No hay datos en humanos disponibles sobre el efecto de Odefsey en la fertilidad. Los estudios realizados en animales no indican efectos dañinos de emtricitabina, rilpivirina hidrocloruro o tenofovir alafenamida sobre la fertilidad (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.3).</span></p></div></text></section><section id="e21ceb98-7661-40f5-b1e2-c16a103656b2"><title value="4.7. Efectos sobre la capacidad para conducir y utilizar máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029815" /><display value="Efectos sobre la capacidad para conducir y utilizar máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt; background-color:#ffffff" ><span style="font-family:Times New Roman; font-size:11pt">Se debe informar a los pacientes de que se han notificado casos de fatiga, mareos y somnolencia durante el tratamiento con los componentes de Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">(ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8)</span><span style="font-family:Times New Roman; font-size:11pt">. Esto se debe tener en cuenta a la hora de evaluar la capacidad del paciente para conducir o utilizar máquinas.</span></p></div></text></section><section id="2829ad99-bfe4-430c-bd03-404d0ee0ee5c"><title value="4.8. Reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029816" /><display value="Reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resumen del perfil de seguridad</span></span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Las</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">reacciones adversas más frecuentemente notificadas en los estudios clínicos de pacientes sin tratamiento previo y que tomaron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat fueron náuseas (11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%), diarrea (7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) y cefalea (6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%). Y en pacientes sin tratamiento previo, que recibieron rilpivirina hidrocloruro en combinación con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato, las reacciones adversas más frecuentemente notificadas fueron náuseas (9%), mareos (8%), sueños anormales (8%), cefalea (6%), diarrea (5%) e insomnio (5%).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se identificaron nuevas reacciones adversas hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 en 2 estudios clínicos de pacientes virológicamente suprimidos que cambiaron desde emtricitabina/rilpivirina/tenofovir disoproxilo fumarato (FTC/RPV/TDF) a Odefsey (estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216) o desde efavirenz/emtricitabina/tenofovir disoproxilo fumarato (EFV/FTC/TDF) a Odefsey (estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160).</span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tabla resumen de reacciones adversas</span></span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La evaluación de las reacciones adversas se basa en los datos de seguridad de todos los estudios de fase II y III en los que 2.396 pacientes recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida administrado con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como un comprimido de combinación de dosis fija, datos combinados obtenidos de 686</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes</span><span style="font-family:Times New Roman; font-size:11pt">que recibieron rilpivirina</span><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg</span><span style="font-family:Times New Roman; font-size:11pt">una vez al día en combinación con otros medicamentos</span><span style="font-family:Times New Roman; font-size:11pt">antirretrovirales en los estudios controlados TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215,</span><span style="font-family:Times New Roman; font-size:11pt">754</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes que recibieron Odefsey en</span><span style="font-family:Times New Roman; font-size:11pt">los estudios</span><span style="font-family:Times New Roman; font-size:11pt">GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160, y la experiencia posterior a la comercialización.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Las reacciones adversas de la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 se muestran según el sistema de clasificación de órganos y la mayor frecuencia observada. Las frecuencias se definen como sigue: muy frecuentes (≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/10), frecuentes (≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/100 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/10) o poco frecuentes (≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/1.000 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/100).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2: Tabla de reacciones adversas</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%"><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuencia</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Reacción adversa</span></p></td></tr></thead><tbody><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos de la sangre y del sistema linfático</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Disminución del recue</span><span style="font-family:Times New Roman; font-size:10pt">nto de leucocitos</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, disminución de la hemoglobina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, disminución del recuento de plaquetas</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Poco frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">anemia</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">2</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos del sistema inmunológico</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Poco frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">síndrome de reconstitución inmunitaria</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos del metabolismo y de la nutrición</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muy frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">aumento del colesterol total (en ayunas)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, aumento del colesterol LDL (en ayunas)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">disminución del apetito</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, aumento de triglicéridos (en ayunas)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos psiquiátricos</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muy frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">insomnio</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">depresión</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, sueños anormales</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span><span style="font-family:Times New Roman; font-size:10pt">, trastornos del sueño</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, humor deprimido</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos del sistema nervioso</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muy frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">cefalea</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span><span style="font-family:Times New Roman; font-size:10pt">, mareo</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">somnolencia</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos gastrointestinales</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muy frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">náuseas</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span><span style="font-family:Times New Roman; font-size:10pt">, aumento de la amilasa pancreática</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">dolor abdominal</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span><span style="font-family:Times New Roman; font-size:10pt">, vómitos</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span><span style="font-family:Times New Roman; font-size:10pt">, aumento de la lipasa</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, malestar abdominal</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, sequedad de boca</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:10pt">, flatulencia</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:10pt">, diarrea</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Poco frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">dispepsia</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos hepatobiliares</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muy frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">aumento de transaminasas (AST y/o ALT)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">aumento de la bilirrubina</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos de la piel y del tejido subcutáneo</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">erupción cutánea</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Poco frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">reacciones cutáneas graves con síntomas sistémicos</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">4</span><span style="font-family:Times New Roman; font-size:10pt">, angioedema</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">5,6</span><span style="font-family:Times New Roman; font-size:10pt">, prurito</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:10pt">, urticaria</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">6</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos musculoesqueléticos y del tejido conjuntivo</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Poco frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">artralgia</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td></tr><tr><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; page-break-inside:avoid; line-height:115%; font-size:10pt"><em><span style="font-family:Times New Roman; font-size:10pt;">Trastornos generales y alteraciones en el lugar de administración</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:25%"><p style="margin:0pt; page-break-inside:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Frecuentes:</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:75%"><p style="margin:0pt; page-break-inside:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">fatiga</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">1,3</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:121.4pt; border:none">
                                        </td>
                                        <td style="width:364.25pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">1</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Reacciones adversas identificadas a partir de estudios clínicos con rilpivirina.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">2</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Esta reacción adversa no se observó en los estudios clínicos de fase</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">III de</span><span style="font-family:Times New Roman; font-size:9pt">emtricitabina</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">+</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">tenofovir</span><span style="font-family:Times New Roman; font-size:9pt">alafenamida en combinación con</span><span style="font-family:Times New Roman; font-size:9pt">elvitegravir</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">+</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">cobicistat</span><span style="font-family:Times New Roman; font-size:9pt">o en estudios de fase III con Odefsey, pero fue identificada a partir de estudios clínicos o de la experiencia poscomercialización para emtricitabina cuando se utilizó con otros antirretrovirales.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">3</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Reacciones adversas identificadas a partir de estudios clínicos de productos que contienen</span><span style="font-family:Times New Roman; font-size:9pt">emtricitabina</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">+</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">tenofovir</span><span style="font-family:Times New Roman; font-size:9pt">alafenamida.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">4</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Reacción adversa</span><span style="font-family:Times New Roman; font-size:9pt">identificada mediante la vigilancia poscomercialización para emtricitabina/rilpivirina/tenofovir disoproxilo fumarato.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">5</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Reacción adversa</span><span style="font-family:Times New Roman; font-size:9pt">identificada mediante la vigilancia poscomercialización para productos con emtricitabina.</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">6</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Reacción adversa</span><span style="font-family:Times New Roman; font-size:9pt">identificada mediante la vigilancia poscomercialización para productos con tenofovir alafenamida.</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:10.5pt"><strong><span style="font-family:Times New Roman; font-size:10.5pt;"> </span></strong></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resultados anómalos de laboratorio</span></span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Cambios en la creatinina sérica en pautas que contienen rilpivirina</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los datos combinados de los estudios de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">III TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215 con pacientes sin tratamiento previo también demuestran que la creatinina sérica aumentó y la tasa de filtración glomerular estimada (TFGe) disminuyó durante 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento con rilpivirina. La mayor parte de este aumento de la creatinina y la disminución de la TFGe se produjo durante las primeras cuatro semanas de tratamiento. A lo largo de 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento con rilpivirina se observaron unos cambios medios de 0,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/dl (intervalo:</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/dl a 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/dl) para la creatinina y</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">13,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min/1,73</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">(intervalo:</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">63,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min/1,73</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">a 40,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min/1,73</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">) para la TFGe. En los pacientes que entraron en los estudios con insuficiencia renal leve o moderada, el aumento de la creatinina sérica observado fue similar a lo observado en pacientes con función renal normal. Estos aumentos no reflejan un cambio en la tasa real de filtración glomerular (TFG).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Cambios en las pruebas de laboratorio de lípidos</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En estudios en pacientes sin tratamiento previo,</span><span style="font-family:Times New Roman; font-size:11pt">que recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida (FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TAF) o emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato (FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TDF), ambos administrados con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimidos de combinación de dosis fija, se observaron aumentos con respecto al valor basal en ambos grupos de tratamiento para los parámetros lipídicos en condiciones de ayuno de colesterol total, colesterol directo ligado a lipoproteínas de baja densidad (LDL) y a lipoproteínas de alta densidad (HDL) y triglicéridos en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">144. La mediana del aumento con respecto al valor basal de dichos parámetros fue mayor en los pacientes que recibieron FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TAF en comparación con los pacientes que recibieron FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TDF (p &lt; 0,001 para la diferencia entre los grupos de tratamiento para el colesterol total en condiciones de ayuno, el colesterol LDL directo y HDL y los triglicéridos). La mediana (Q1, Q3) del cambio con respecto al valor basal en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">144 en el cociente colesterol total/colesterol HDL fue de 0,2 (</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,3; 0,7) en pacientes que recibieron FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TAF y de 0,1 (</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,4; 0,6) en pacientes que recibieron FTC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">TDF (p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,006 para la diferencia entre los grupos de tratamiento).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El cambio de una pauta basada en TDF a Odefsey puede provocar ligeros aumentos en los parámetros lipídicos.</span><span style="font-family:Times New Roman; font-size:11pt">En un estudio de pacientes virológicamente suprimidos que cambiaron desde FTC/RPV/TDF a Odefsey (estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216), se observaron aumentos desde el inicio en los valores en ayunas del colesterol total, colesterol LDL directo, colesterol HDL y triglicéridos en el brazo de Odefsey, y no se observaron cambios clínicamente significativos desde el inicio en la mediana de los valores en ayunas para el cociente colesterol total/colesterol HDL en ambos grupos de tratamiento, en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96. En un estudio con pacientes virológicamente suprimidos que cambiaron desde EFV/FTC/TDF a Odefsey (estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160), se observaron reducciones desde el inicio en los valores en ayunas del colesterol total y colesterol HDL en el grupo de Odefsey; no se observaron cambios clínicamente significativos desde el inicio en la mediana de los valores en ayunas para el cociente colesterol total/colesterol HDL, colesterol LDL directo o triglicéridos en ambos grupos de tratamiento en la semana 96.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Cortisol</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En los estudios de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">III TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215 combinados de pacientes sin tratamiento previo, en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96, hubo una media del cambio global con respecto al valor basal de cortisol de</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">19,1 (</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">30,85;</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">7,37)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nmol/l en el grupo de rilpivirina y de</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,6 (</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">13,29; 12,17)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nmol/l en el grupo de efavirenz. En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96, el cambio medio con respecto al valor basal en la concentración de cortisol estimulado por ACTH fue menor en el grupo de rilpivirina (+18,4 ± 8,36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nmol/l) que en el grupo de efavirenz (+54,1 ± 7,24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nmol/l). Los valores medios para el grupo de rilpivirina tanto para el cortisol basal como el estimulado por ACTH en la semana 96, se mantuvieron dentro del intervalo normal. Estos cambios en los parámetros de seguridad suprarrenal no fueron clínicamente relevantes. No hubo signos ni síntomas clínicos que sugirieran insuficiencia suprarrenal o disfunción gonadal en adultos.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Descripción de las reacciones adversas seleccionadas</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Parámetros metabólicos</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El peso y los niveles de glucosa y lípidos en la sangre pueden aumentar durante el tratamiento antirretroviral (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Síndrome de reconstitución inmunitaria</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Al inicio de la TARC, en los pacientes infectados por VIH con deficiencia inmunitaria grave, puede aparecer una reacción inflamatoria frente a infecciones oportunistas latentes o asintomáticas. Se han notificado también trastornos autoinmunitarios (como la enfermedad de Graves y la hepatitis autoinmune). No obstante, el tiempo hasta el inicio notificado es más variable y estos eventos pueden producirse muchos meses después del inicio del tratamiento (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Osteonecrosis</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se han notificado casos de osteonecrosis, especialmente en pacientes con factores de riesgo generalmente reconocidos, enfermedad avanzada por VIH o exposición prolongada a la TARC. Se desconoce la frecuencia de esta reacción adversa (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Reacciones cutáneas graves</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se han notificado reacciones cutáneas graves con síntomas sistémicos durante la experiencia poscomercialización de emtricitabina/rilpivirina/tenofovir disoproxilo fumarato, incluidas erupciones acompañadas por fiebre, ampollas, conjuntivitis, angioedema, elevaciones en las pruebas de la función hepática y/o eosinofilia.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La seguridad de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida se evaluó a lo largo de 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas en un estudio clínico abierto (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0106) en el que 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 de 12 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad que nunca habían recibido tratamiento recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimido de combinación a dosis fija. En este estudio, el perfil de seguridad en pacientes adolescentes fue similar al de los adultos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La evaluación de la seguridad de rilpivirina se basó en los datos a 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, de un estudio abierto de un solo grupo (TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C213) en 36 pacientes pediátricos de 12 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años y con un peso mínimo de 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg. Ningún paciente interrumpió la toma de rilpivirina debido a reacciones adversas. No se identificaron nuevas reacciones adversas en comparación a las observadas en adultos. La mayoría de las reacciones adversas fueron de grado 1 o 2. Las reacciones adversas (todos los grados) muy frecuentes fueron cefalea, depresión, somnolencia y náuseas. No se informó de ningún resultado anómalo de laboratorio de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4 para AST/ALT o reacciones adversas de grado 3</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4 de aumento de transaminasas (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Otras poblaciones especiales</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes con insuficiencia renal</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La seguridad de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida se evaluó a lo largo de 144</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas en un estudio clínico abierto (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0112) en el que 248</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 que o bien nunca habían recibido tratamiento previo (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6), o bien eran pacientes virológicamente suprimidos (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">242), con insuficiencia renal leve o moderada (tasa de filtración glomerular estimada mediante el método de Cockcroft</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Gault [TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt">]: 30</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">69</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimido de combinación a dosis fija. El perfil de seguridad en pacientes con insuficiencia renal leve o moderada fue similar al de los pacientes con función renal normal (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La seguridad de emtricitabina + tenofovir alafenamida se evaluó durante 48 semanas en un estudio clínico abierto, de un solo brazo (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1825) en el que 55 pacientes infectados por VIH-1, virológicamente suprimidos y con nefropatía terminal (TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) en hemodiálisis crónica recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimido de combinación a dosis fija. No se identificaron problemas de seguridad nuevos en pacientes con nefropatía terminal en hemodiálisis crónica tratados con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir + cobicistat como comprimido de combinación a dosis fija (ver sección 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes coinfectados por el VIH y el VHB</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La seguridad de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir y cobicistat como comprimido de combinación a dosis fija (elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida [E/C/F/TAF]) se evaluó en 72</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes coinfectados por VIH/VHB que recibieron tratamiento para el VIH en un estudio clínico abierto (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1249), hasta la semana 48, en el que los pacientes cambiaron de una pauta antirretroviral (que incluía TDF en 69 de 72 pacientes) a E/C/F/TAF. Según estos datos limitados, el perfil de seguridad de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir y cobicistat como comprimido de combinación a dosis fija en pacientes coinfectados por VIH/VHB fue similar al de los pacientes monoinfectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En pacientes coinfectados por el virus de la hepatitis B o C que recibieron rilpivirina, la incidencia de elevación de enzimas hepáticas fue mayor que en los pacientes que recibieron rilpivirina y que no estaban coinfectados. La exposición farmacocinética de rilpivirina en pacientes coinfectados fue comparable a la de pacientes sin coinfección.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text><section id="b01f9ab5-c976-4d5f-93b5-609d2b23c252"><title value="4.8.2. Notificación de sospechas de reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029818" /><display value="Notificación de sospechas de reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante notificar sospechas de reacciones adversas al medicamento tras su autorización. Ello p</span><span style="font-family:Times New Roman; font-size:11pt">ermite una supervisión continuada de la relación beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#cccccc">sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-family:Times New Roman; font-size:11pt; background-color:#cccccc">Apéndice</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#cccccc"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#cccccc">V</span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p></div></text></section></section><section id="65884306-ef61-42f6-a802-61cb0ac39b05"><title value="4.9. Sobredosis" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029819" /><display value="Sobredosis" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En caso de sobredosis, se debe vigilar al paciente por si hay evidencia de toxicidad (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8), y administrar el tratamiento de apoyo si fuera necesario, incluyendo la observación de la situación clínica del paciente y la monitorización de las constantes vitales y ECG (intervalo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">QT).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No existe ningún antídoto específico para la sobredosis con Odefsey. Hasta el 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis de emtricitabina puede eliminarse por hemodiálisis. Tenofovir se elimina eficazmente mediante hemodiálisis con un coeficiente de extracción de aproximadamente el 54</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%. Se desconoce si emtricitabina o tenofovir se pueden eliminar con diálisis peritoneal. Puesto que rilpivirina presenta una elevada unión a proteínas, es improbable que la diálisis dé como resultado una eliminación significativa del principio activo. Se debe hacer un control adicional según se indique clínicamente o lo recomiende el centro de toxicología nacional, si se dispone.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="a554428d-6499-470b-abd6-c75469c561f1"><title value="5. Propiedades farmacológicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029821" /><display value="Propiedades farmacológicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="84e40ea6-d014-4c1c-ae15-4928e5acad75"><title value="5.1. Propiedades farmacodinámicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029822" /><display value="Propiedades farmacodinámicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Grupo farmacoterapéutico: Antiviral para uso sistémico; antivirales para el tratamiento de infecciones por VIH y combinaciones, código ATC: J05AR19</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mecanismo de acción y efectos farmacodinámicos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Emtricitabina es un inhibidor de la transcriptasa inversa análogo de nucleósidos (ITIAN) y un análogo de 2’</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">desoxicitidina. Emtricitabina es fosforilada por enzimas celulares para formar emtricitabina trifosfato. Emtricitabina trifosfato inhibe competitivamente la transcriptasa inversa (TI) del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, lo que da c</span><span style="font-family:Times New Roman; font-size:11pt">omo resultado la terminación de la cadena de ácido desoxirribonucleico (ADN). Emtricitabina muestra actividad frente al VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 y el VHB.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina es un ITINN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 del grupo de las diarilpirimidinas. La actividad de rilpivirina está mediada por la inhibición no competitiva de la TI del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1. Rilpivirina no inhibe las polimerasas del ADN celulares humanas α, β, ni la polimerasa</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">del ADN mitocondrial γ.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida es un</span><span style="font-family:Times New Roman; font-size:11pt">inhibidor de la transcriptasa inversa análogo de nucleótidos</span><span style="font-family:Times New Roman; font-size:11pt">(ITIANt) y</span><span style="font-family:Times New Roman; font-size:11pt">un profármaco de tenofovir (análogo de 2’</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">desoxiadenosina monofosfato). Debido a su mayor estabilidad plasmática y activación intracelular mediante hidrólisis por la catepsina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">A, tenofovir alafenamida es más eficaz que tenofovir disoproxilo fumarato a la hora de concentrar tenofovir en las células mononucleares de sangre periférica (PBMC,</span><em><span style="font-family:Times New Roman; font-size:11pt;">peripheral blood mononuclear cells</span></em><span style="font-family:Times New Roman; font-size:11pt">) (incluidos linfocitos y otras células diana del VIH) y los macrófagos. Tenofovir intracelular se fosforila a continuación al metabolito activo tenofovir difosfato. Tenofovir difosfato inhibe la TI</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">del VIH, lo que da como resultado la terminación de la cadena de ADN. Tenofovir muestra actividad frente al VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 y el VHB.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Actividad antiviral</span></span><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">in</span></span></em><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span></em><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Las combinaciones de emtricitabina, rilpivirina y tenofovir alafenamida no fueron antagónicas y mostraron efectos sinérgicos en estudios de actividad antiviral combinada en cultivo celular.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La actividad antiviral de emtricitabina frente a aislados clínicos y de laboratori</span><span style="font-family:Times New Roman; font-size:11pt">o del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 se evaluó en líneas celulares linfoblastoides, en la línea celular MAGI</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">CCR5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y en PBMC. Los valores de la concentración eficaz al 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">) para emtricitabina oscilaron entre 0,0013</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y 0,64</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μM. Emtricitabina mostró actividad antiviral en cultivos celulares frente a los subtipos del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 A, B, C, D, E, F y G (con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">de 0,007</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">a 0,075</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µM) y presentó actividad frente al VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 (con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">de 0,007</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">a 1,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µM).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina mostró actividad frente a cepas de laboratorio del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt">de tipo salvaje en una línea de linfocitos T infectados de forma aguda, con un valor mediano de la CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">para VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1/IIIB de 0,73</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM (0,27 ng/ml). Rilpivirina demostró también actividad antiviral frente a un amplio panel de aislados primarios del grupo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">M de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 (subtipo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">A, B, C, D, F, G, H) con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">que varían desde 0,07 hasta 1,01</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM (0,03 a 0,37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ng/ml), aislados primarios del grupo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">O con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">que varían desde 2,88 hasta 8,45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM (de 1,06 a 3,10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ng/ml), y mostró actividad limitada</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">contra el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">que varían desde 2.510 hasta 10.830</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM (de 920 a 3.970</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ng/ml).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La actividad antiviral de tenofovir alafenamida frente a aislados clínicos y de laboratorio del subtipo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 se evaluó en líneas celulares linfoblastoides, PBMC, células monocíticas/macrofágicas primarias y linfocitos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">T</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4+. Los valores de la CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">de</span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida</span><span style="font-family:Times New Roman; font-size:11pt">oscilaron entre 2,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y 14,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM.</span><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida</span><span style="font-family:Times New Roman; font-size:11pt">mostró actividad antiviral en cultivos celulares frente a todos los grupos del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 (M, N, O), incluyendo los subtipos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">A, B, C, D, E, F y G (con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">de 0,10 a 12,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM) y mostró actividad frente al VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 (con valores de CE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">de 0,91 a 2,63</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM).</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resistencia</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Considerando todos los datos</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">disponibles y los datos generados en pacientes sin tratamiento previo, las siguientes mutaciones asociadas a resistencia en la TI del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, cuando se encuentran presentes en la situación basal, pueden afectar a la actividad de Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L y la combinación de L100I y K103N.</span></p><p style="margin:0pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:TimesNewRomanPSMT; font-size:11pt">No se puede excluir un impacto negativo por mutaciones de ITINN distintas a las enumeradas anteriormente (por ejemplo, mutaciones K103N o L100I como mutaciones únicas), ya que esto no se estudió</span><em><span style="font-family:TimesNewRomanPS-ItalicMT; font-size:11pt;">in vivo</span></em><span style="font-family:TimesNewRomanPSMT; font-size:11pt">en un número suficiente de pacientes</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Al igual que con otros medicamentos antirretrovirales, la realización de pruebas de resistencia y/o los antecedentes de resistencias deben guiar el uso de Odefsey (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">In</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La sensibilidad reducida a emtricitabina se asocia con mutaciones M184V/I en la TI</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se seleccionaron cepas resistentes a rilpivirina en cultivo celular a partir de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 de tipo salvaje de diferentes orígenes y subtipos, así como VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 resistentes a ITINN. Las sustituciones de aminoácidos más frecuentemente observadas que surgieron fueron: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C y M230I.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los aislados del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 con sensibilidad reducida a tenofovir alafenamida expresaron una mutación K65R en la TI</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1. Además, se ha observado de forma transitoria una mutación K70E en la TI del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos sin tratamiento previo</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 144, en un análisis combinado de pacientes sin tratamiento previo antirretroviral tratados con</span><span style="font-family:Times New Roman; font-size:11pt">elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (E/C/F/TAF) en los estudios de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">III GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0104 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0111, se observó el desarrollo de una o más mutaciones asociadas a resistencia primaria en aislados de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 en 12 de 866</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) pacientes tratados con E/C/F/TAF. Entre estos 12 aislados de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, las mutaciones que surgieron fueron M184V/I (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">11) y K65R/N (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2) en la TI y T66T/A/I/V (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2), E92Q (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4), Q148Q/R (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1) y N155H (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2) en la integrasa.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 96, en un análisis combinado de pacientes que habían recibido tratamiento con emtricitabina/tenofovir disoproxilo fumarato (FTC/TDF) + rilpivirina hidrocloruro en los estudios clínicos de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">III TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215, en aislados de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 de 43</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes</span><span style="font-family:Times New Roman; font-size:11pt">había una sustitución de aminoácidos asociada con resistencia a ITINN (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">39) o ITIAN (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">41). Las mutaciones asociadas a resistencia a ITINN que se desarrollaron más frecuentemente fueron: V90I, K101E, E138K/Q, V179I, Y181C, V189I, H221Y y F227C. La presencia de V90I y V189I en el momento basal no afectó a la respuesta. El cincuenta y dos por ciento de aislados de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 con resistencia emergente en el grupo de rilpivirina desarrollaron mutaciones c</span><span style="font-family:Times New Roman; font-size:11pt">oncomitantes relacionadas con ITINN e ITIAN, las más frecuentes E138K y M184V. Las mutaciones asociadas con la resistencia a ITIAN que se desarrollaron en 3 o más cultivos aislados de pacientes fueron: K65R, K70E, M184V/I y K219E.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96, menos pacientes en el grupo de rilpivirina con carga viral basal ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml tuvieron sustituciones asociadas a resistencia emergente y/o resistencia fenotípica a rilpivirina (7/288) que los pacientes con carga viral basal &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (30/262).</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">En pacientes virológicamente suprimidos</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se identificó un paciente con resistencia de reciente aparición (M184M/I) en un estudio clínico de pacientes virológicamente suprimidos que cambiaron desde una pauta que contenía emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato a E/C/F/TAF en un comprimido de combinación de dosis fija (CDF) (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0109, n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">959).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96, en los pacientes que cambiaron a Odefsey desde emtricitabina/rilpivirina/tenofovir disoproxilo fumarato (FTC/RPV/TDF) o efavirenz/emtricitabina/tenofovir disoproxilo fumarato (EFV/FTC/TDF) (estudios GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160; n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">754), no se detectaron mutaciones asociadas a resistencia aparecidas durante el tratamiento.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes coinfectados por el VIH y el VHB</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En un estudio clínico en pacientes coinfectados por el VIH virológicamente suprimidos y hepatitis B crónica, que recibieron E/C/F/TAF durante 48 semanas (GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1249, n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">72), 2 pacientes cumplieron las condiciones para un análisis de resistencia. En estos 2 pacientes, no se identificaron en el VIH-1 o el VHB sustituciones de aminoácidos asociadas a resistencia a alguno de los componentes de E/C/F/TAF.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resistencia cruzada</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los virus resistentes a emtricitabina con la sustitución M184V/I mostraron resistencia cruzada con lamivudina, pero conservaron la sensibilidad a didanosina, estavudina, tenofovir y zidovudina.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En un panel de 67 cepas de laboratorio de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 recombinantes con una mutación asociada a resistencia en posiciones de la TI asociadas con resistencia a ITINN, las únicas mutaciones individuales asociadas a resistencia asociadas con una pérdida de sensibilidad a rilpivirina fueron K101P y Y181V/I. La sustitución K103N sola no dio lugar a una susceptibilidad reducida a rilpivirina, pero la combinación de K103N y L100I dio lugar a una sensibilidad 7 veces menor a rilpivirina. En otro estudio, la sustitución Y188L dio lugar a una reducción de la sensibilidad a rilpivirina de 9 veces para los aislados clínicos y de 6 veces para los mutantes de sitio dirigido.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En los pacientes que recibieron rilpivirina hidrocloruro en combinación con FTC/TDF en estudios de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">III (datos combinados de TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215), la mayoría de aislados de VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 con resistencia fenotípica emergente a rilpivirina tenía resistencia cruzada a al menos otro ITINN (28/31).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La sustitución K65R y también K70E redunda en una sensibilidad reducida a abacavir, didanosina, lamivudina, emtricitabina y tenofovir, pero conserva la sensibilidad a zidovudina.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Datos clínicos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La eficacia clínica de Odefsey se estableció a partir de estudios realizados con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida administrada con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimido de CDF de E/C/F/TAF, a partir de estudios realizados con rilpivirina administrada con FTC/TDF como componentes individuales o como un comprimido de CDF de FTC/RPV/TDF, y a partir de estudios realizados con Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pautas de tratamiento que contienen emtricitabina</span></em><span style="font-family:Times New Roman; font-size:11pt"> </span><em><span style="font-family:Times New Roman; font-size:11pt;">+</span></em><span style="font-family:Times New Roman; font-size:11pt"> </span><em><span style="font-family:Times New Roman; font-size:11pt;">tenofovir alafenamida</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos sin tratamiento previo y virológicamente suprimidos, infectados por VIH</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">1</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0104 y el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0111, los pacientes recibieron E/C/F/TAF (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">866) o bien</span><span style="font-family:Times New Roman; font-size:11pt">elvitegravir/cobicistat/emtricitabina/tenofovir disoproxilo fumarato (</span><span style="font-family:Times New Roman; font-size:11pt">E/C/F/TDF) (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">867) una vez al día, ambos administrados como comprimidos de CDF.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La media de edad fue de 36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 18</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">76), el 85</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran hombres, el 57</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% blancos, el 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% negros y el 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% asiáticos. La media del ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 plasmático basal fue de 4,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">log</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (rango 1,3</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">7,0) y el 23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de los pacientes tenía cargas virales basales de &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml. La media del recuento basal de células CD4+ fue de 427</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 0</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.360) y el 13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% tenía cifras de células CD4+ &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En los estudios GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0104 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0111, E/C/F/TAF demostró superioridad estadística en cuanto a la consecución de un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml al compararlo con E/C/F/TDF en la semana 144. La diferencia en porcentaje fue de 4,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%: 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% a 7,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%). Los resultados combinados de los tratamientos a las 48 y a las 144</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas se muestran en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0109, se evaluaron la eficacia y la seguridad de cambiar desde EFV/FTC/TDF, FTC/TDF más atazanavir (potenciado con cobicistat o con ritonavir) o comprimido de CDF de E/C/F/TDF a E/C/F/TAF en un estudio abierto aleatorizado de adultos infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 virológicamente suprimidos (ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml) (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">959 cambiaron a E/C/F/TAF, n = 477 permanecieron con la pauta basal). Los pacientes tenían una media de edad de 41</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 21</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">77), el 89</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran hombres, el 67</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% blancos y el 19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% negros. La media del recuento basal de células CD4+ fue de 697</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 79</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.951).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0109, el cambio desde una pauta basada en tenofovir disoproxilo fumarato a E/C/F/TAF fue superior a la hora de mantener un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml en comparación con permanecer con la pauta basal. Los resultados combinados de los tratamientos a las 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas se muestran en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">3: Resultados virológicos de los estudios GS</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0104, GS</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0111 en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48 y la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">144</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">, y GS</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0109 en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100.56%" ><thead><tr style="height:7.3pt"><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td colspan="5" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Pacientes adultos que nunca habían recibido tratamiento, en los estudios GS</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">0104 y GS</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">0111</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">b</span></strong></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Adultos virológicamente suprimidos en el estudio GS</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">292</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">0109</span></strong></p></td></tr><tr style="height:7.3pt"><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Semana</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">48</span></strong></p></td><td colspan="3" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Semana</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">144</span></strong></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Semana</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">48</span></strong></p></td></tr><tr style="height:7.3pt"><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">E/C/F/TAF</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">866)</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">E/C/F/TDF</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">867)</span></strong></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">E/C/F/TAF</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">866)</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">E/C/F/TDF</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">867)</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">E/C/F/TAF</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">959)</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Pauta basal</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(n</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">477)</span></strong></p></td></tr></thead><tbody><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">1 &lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">50</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">92</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">90</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">84</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">80</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">97</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">93</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr style="height:13pt"><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Diferencia entre tratamientos</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2,0</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%:</span><br /><span style="font-family:Times New Roman; font-size:10pt">-0,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% a 4,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%)</span></p></td><td colspan="3" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%:</span><br /><span style="font-family:Times New Roman; font-size:10pt">0,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% a 7,8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%)</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4,1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%:</span><br /><span style="font-family:Times New Roman; font-size:10pt">1,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% a 6,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%, p</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">&lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">0,001</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr style="height:12.15pt"><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">1 ≥</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">50</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">d</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Ausencia de datos virológicos en la</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">ventana de la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">48 o 144</span></strong></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">11</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">16</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Interrumpieron la medicación del estudio debido a AA o muerte</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">e</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Interrumpieron la medicación del estudio debido a otros motivos y último ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">disponible &lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">f</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">11</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Datos ausentes (missing data) durante la ventana pero en tratamiento con la medicación del estudio</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">0</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">1 &lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">20</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">84</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">84</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">81</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:10.92%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">76</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Diferencia entre tratamientos</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">0,4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%:</span><br /><span style="font-family:Times New Roman; font-size:10pt">-3,0</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% a 3,8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%)</span></p></td><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">5,4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (IC del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%:</span><br /><span style="font-family:Times New Roman; font-size:10pt">1,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% a 9,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Proporción (%) de pacientes con ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">1 &lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">50</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml con la pauta de tratamiento previo</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">d</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.3%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt; background-color:#c0c0c0"> </span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">EFV/FTC/TDF</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.3%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">96</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">90</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">FTC/TDF más refuerzo con atazanavir</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.3%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">97</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">92</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr><tr><td style="background-color:#ffffff; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:24.9%"><p style="margin:0pt 0pt 0pt 17.4pt"><span style="font-family:Times New Roman; font-size:10pt">E/C/F/TDF</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.44%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.3%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:12.42%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">98</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:14.4%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">97</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">%</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:106.65pt; border:none">
                                        </td>
                                        <td style="width:53.25pt; border:none">
                                        </td>
                                        <td style="width:53.5pt; border:none">
                                        </td>
                                        <td style="width:52.65pt; border:none">
                                        </td>
                                        <td style="width:0.5pt; border:none">
                                        </td>
                                        <td style="width:46.75pt; border:none">
                                        </td>
                                        <td style="width:53.15pt; border:none">
                                        </td>
                                        <td style="width:61.65pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; padding-left:14.4pt" ><span style="font-family:Times New Roman; font-size:9pt">a</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">La ventana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 fue entre los días</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">294 y 377 (ambos inclusive); la ventana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">144 fue entre los días</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">966 y 1.049 (ambos inclusive).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">b</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">En ambos estudios se estratificó a los pacientes según su ARN del VIH</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">1 basal (≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml, &gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml a ≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">400.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml o &gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">400.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml), según el recuento de células CD4+ (&lt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">50</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/μl, 50</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">199</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/μl o ≥</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/μl) y según la región (EE.</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">UU. o fuera de EE.</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">UU.)</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">c</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">El valor de p para la prueba de superioridad que comparaba los porcentajes de éxito virológico fue el de la prueba de CMH (Cochran</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">Mantel</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">Haenszel) estratificada según la pauta de tratamiento previo (EFV/F</span><span style="font-family:Times New Roman; font-size:9pt">TC/TDF, FTC/TDF más refuerzo con atazanavir o E/C/F/TDF).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; padding-left:14.2pt" ><span style="font-family:Times New Roman; font-size:9pt">d</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Incluye a pacientes que tenían ≥</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">50</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml en la ventana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 o 144, pacientes que interrumpieron precozmente debido a ausencia o pérdida de la eficacia, pacientes que interrumpieron por motivos distintos de un acontecimiento adverso (AA), muerte o ausencia o pérdida de eficacia y que en el momento del abandono tenían un valor viral ≥</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">50</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; padding-left:14.2pt" ><span style="font-family:Times New Roman; font-size:9pt">e</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Incluye a pacientes que interrumpieron debido a un AA o muerte en cualquier momento d</span><span style="font-family:Times New Roman; font-size:9pt">esde el día</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">1 hasta la ventana temporal, si esto dio lugar a una ausencia de datos virológicos sobre el tratamiento durante la ventana especificada.</span></p><p style="margin:0pt; text-indent:-14.2pt; padding-left:14.2pt" ><span style="font-family:Times New Roman; font-size:9pt">f</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Incluye a pacientes que interrumpieron por motivos distintos de un AA, muerte o ausencia o pérdida de eficacia, p.</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">ej., que retiraron el consentimiento, se perdieron para el seguimiento, etc.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En los estudios GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0104 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0111, la tasa de eficacia virológica fue similar entre los subgrupos de pacientes (edad, sexo, raza, ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 basal, o recuento de células CD4+ basal).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">El aumento medio con respecto al valor basal en el recuento de células CD4+ fue 230</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los pacientes tratados con E/C/F/TAF y 211</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los pacientes tratados con E/C/F/TDF (p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,024) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 y 326</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los pacientes tratados con E/C/F/TAF y 305</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los pacientes tratados con E/C/F/TDF (p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,06) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">144.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pautas de tratamiento que contienen rilpivirina</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos sin tratamiento previo, infectados por VIH</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">1</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La eficacia de rilpivirina se basa en el análisis de datos de 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas a partir de dos estudios aleatorizados, controlados, doble ciego, en pacientes sin tratamiento previo (TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y subconjunto de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato en TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el análisis combinado de 1096 pacientes del TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215 que recibieron una pauta anterior (PA) de FTC/TDF, las características demográficas y basales fueron equilibradas entre los grupos de rilpivirina y efavirenz (EFV). La mediana de edad fue de 36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años, el 78</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran varones y el 62</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% blancos y el 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% negros/afroamericanos. La mediana del ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 plasmático fue de 5,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">log</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml y la mediana del recuento de células</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4+ fue de 255</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La respuesta global y un análisis de subgrupos de la respuesta virológica (ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml) tanto a las 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas como a las 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, y el fracaso virológico desde la carga viral basal (datos combinados de los dos estudios clínicos de fase III, TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C209 y TMC278</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">C215, para pacientes que recibieron la PA de FTC/TDF) se presentan en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">4:</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">Resultados virológicos del tratamiento aleatorizado de los estudios TMC278</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">C209 y TMC278</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">C215 (datos agrupados de los pacientes que recibieron rilpivirina hidrocloruro o efavirenz en combinación con FTC/TDF) en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48 (primario) y la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">96</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:464.65pt" ><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">RPV + FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(n</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">=</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">EFV + FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(n</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">=</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">RPV + FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(n</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">=</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">EFV + FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">(n</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">=</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">546)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:183.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">48</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:183.9pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">96</span></p></td></tr></thead><tbody><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Respuesta global (ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">cop</span><span style="font-family:Times New Roman; font-size:10pt">ias/ml (TLOVR</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:10pt">))</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">83,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (459/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">82,4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (450/546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">76,9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (423/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">77,3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (422/546)</span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:464.65pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Por carga viral basal (copias/ml</span><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">89,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (258/288)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">84,8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (217/256)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">83,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (241/288)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">80,8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (206/255)</span></p></td></tr><tr style="height:13.1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">76,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (201/262)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">80,3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (233/290)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">69,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (182</span><span style="font-family:Times New Roman; font-size:10pt">/262)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">74,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (216/291)</span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:464.65pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Sin respuesta</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Fracaso virológico (todos los pacientes)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">9,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (52/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (23/546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">11,5</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (63/550)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">5,1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (28/546)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">d</span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:464.65pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Por carga viral basal (copias/ml</span><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (12/288)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">2,3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (6/256)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">5,9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (17/288)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">2,4</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (6/255)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.00</span><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">15,3</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (40/262)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">5,9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (17/290)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">17,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (46/262)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">7,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (22/291)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Muerte</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (1/546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0,7</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (4/546)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interrupción debido a acontecimiento adverso (AA)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">2,2</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (12/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">7,1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (39/546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">3,6</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (20/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">8,1</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (44/546)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interrupción por motivos distintos de un AA</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">e</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:86.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4,9</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (27/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:97pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">6,0</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (33/546)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:91.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (44/550)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.85pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">8,8</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% (48/546)</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:97.55pt; border:none">
                                        </td>
                                        <td style="width:86.2pt; border:none">
                                        </td>
                                        <td style="width:97pt; border:none">
                                        </td>
                                        <td style="width:91.05pt; border:none">
                                        </td>
                                        <td style="width:92.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">EFV = efavirenz; RPV = rilpivirina</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">a</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">ITT TLOVR</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Intención de tratar, tiempo hasta la pérdida de respuesta virológica.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">b</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">La diferencia en la tasa de respuesta en la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 es del 1</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">% (inter</span><span style="font-family:Times New Roman; font-size:9pt">valo de confianza del 95</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">%, -3</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">% a 6</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">%) usando una aproximación normal.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">c</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Hubo 17 nuevos fracasos virológicos entre el análisis primario de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 y la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">96 (6</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">pacientes con carga viral basal ≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml y 11</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">pacientes con carga viral basal &gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml). También hubo reclasificaciones en el análisis primario de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 siendo la más frecuente la reclasificación de fracaso virológico a abandonaron por motivos distintos de un AA.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">d</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Hubo 10 nuevos fracasos virológicos entre el análisis primario de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 y la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">96 (3</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">pacientes con carga viral basal ≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml y 7</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">pacientes con carga viral basal &gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml). También hubo reclasificaciones en el análisis primario de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 siendo la reclasificació</span><span style="font-family:Times New Roman; font-size:9pt">n más frecuente de fracaso virológico a abandonaron por motivos distintos de un AA.</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">e</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">p.</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">ej., pérdida para el seguimiento, falta de cumplimiento, retiraron el consentimiento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">FTC/TDF + rilpivirina hidrocloruro fue no inferior a la hora de lograr un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml comparado con FTC/TDF</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">efavirenz.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pauta de tratamiento con Odefsey</span></em></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos virológicamente suprimidos infectados por VIH</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">1</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216 se evaluó la eficacia y seguridad del cambio desde FTC/RPV/TDF a Od</span><span style="font-family:Times New Roman; font-size:11pt">efsey en un estudio aleatorizado, doble ciego, con pacientes adultos infectados por VIH-1 virológicamente suprimidos. Los pacientes tenían una edad media de 45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 23−72), el 90% eran varones, el 75% eran blancos, y el 19% eran negros. La media del</span><span style="font-family:Times New Roman; font-size:11pt">recuento basal de células CD4+ fue de 709</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 104</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2.527).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160 se evaluó la eficacia y la seguridad del cambio desde EFV/FTC/TDF a Odefsey en un estudio aleatorizado, doble ciego, con pacientes adultos infectados por VIH-1 virológicamente suprimidos. Los pacientes tenían una edad media de 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 19−76), el 87% eran varones, el 67% eran blancos, y el 27% eran negros. La media del recuento basal de células CD4+ fue de 700</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 140−1.862).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffff00"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En la</span><span style="font-family:Times New Roman; font-size:11pt">tabla 5 se presentan los resultados del tratamiento de los estudios GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216 y GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">5: Resultados virológicos</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">de los estudios GS</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">366</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1216 y GS</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">US</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">366</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1160 en las semanas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">y 96</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:463.7pt" ><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:191.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">GS</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">US</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">366</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1216</span></p></td><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:185.1pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">GS</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">US</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">366</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1160</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana 48</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana 96</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:89.4pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana 48</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Semana 96</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ODE</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">316)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">FTC/RPV/TDF</span><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">313)</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ODE</span><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">316)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">FTC/RPV/TDF</span><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">313)</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ODE</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">438)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">EFV/</span><span style="font-family:Times New Roman; font-size:10pt">FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">437)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ODE</span><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">438)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">EFV/</span><span style="font-family:Times New Roman; font-size:10pt">FTC/TDF</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:9pt"><span style="font-family:Times New Roman; font-size:9pt">(n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">437)</span></p></td></tr></thead><tbody><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">94%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">94%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">89%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">88%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">90%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">92%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">85%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">85%</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Diferencia de trata</span><span style="font-family:Times New Roman; font-size:10pt">miento</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">0,3% (IC del 95%:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">4,2% a 3,7%)</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0,7% (IC del 95%:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">-4,3% a 5,8%)</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:89.4pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">2,0% (IC del 95%:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">5,9% a 1,8%)</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:95.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0% (IC del 95%:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">-4,8% a 4,8%)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1 ≥</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">d</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Ausencia de datos virológicos en la ventana de la semana</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">48 o</span><span style="font-family:Times New Roman; font-size:10pt">la semana</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">96</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">6%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">6%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">10%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">11%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">9%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">7%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">14%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">14%</span></p></td></tr><tr style="height:13.1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interrupción de la medicación del estudio debido a AA o muerte y último ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1 disponible &lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">2%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">2%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">3%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">3%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">3%</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Interrupción de la medicación del estudio debido a otros motivos y último ARN del VIH</span><span style="font-family:Times New Roman; font-size:10pt">‑</span><span style="font-family:Times New Roman; font-size:10pt">1 disponible &lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">e</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">5%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">5%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">10%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">11%</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:87.35pt"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">Datos ausentes (missing data) durante la ventana pero en tratamiento con la medicación del estudio</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.5pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.75pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:40.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:49.2pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:44.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">&lt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:2.9pt; padding-right:2.9pt; vertical-align:top; width:51pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:10pt"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:87.35pt; border:none">
                                        </td>
                                        <td style="width:44.5pt; border:none">
                                        </td>
                                        <td style="width:51pt; border:none">
                                        </td>
                                        <td style="width:44.75pt; border:none">
                                        </td>
                                        <td style="width:51pt; border:none">
                                        </td>
                                        <td style="width:40.2pt; border:none">
                                        </td>
                                        <td style="width:49.2pt; border:none">
                                        </td>
                                        <td style="width:44.7pt; border:none">
                                        </td>
                                        <td style="width:51pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">ODE</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Odefsey</span></p><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">a</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">La ventana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 fue entre el día</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">295</span><span style="font-family:Times New Roman; font-size:9pt">y el 378 (ambos incluidos).</span></p><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">b</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">La ventana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">96 fue entre el día</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">631 y el 714 (ambos incluidos).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">c</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Se excluyó del análisis a un paciente que no estaba con</span><span style="font-family:Times New Roman; font-size:9pt">FTC/RPV/TDF antes de la selección.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">d</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Incluye a pacientes que tenían</span><span style="font-family:Times New Roman; font-size:9pt">≥</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">50</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml en la v</span><span style="font-family:Times New Roman; font-size:9pt">entana de la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">48 o la semana</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">96, pacientes que interrumpieron precozmente debido a ausencia o pérdida de eficacia, pacientes que interrumpieron por motivos diferentes a la falta o pérdida de eficacia y en el momento del abandono tenían un valor viral de ≥</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">50</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">e</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">Incluye a pacientes que interrumpieron por motivos diferentes a un acontecimiento adverso (AA), muerte o ausencia o pérdida de eficacia,</span><span style="font-family:Times New Roman; font-size:9pt">p. ej., retirada del consentimiento, pérdida de seguimiento, etc.</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 el cambio a</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey fue no-inferior en mantener ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml comparado con pacientes que permanecieron en FTC/RPV/TDF o en EFV/FTC/TDF en los estudios correspondientes.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1216 el cambio medio desde el inicio en el recuento de las células CD4+ en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 fue de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en pacientes que se cambiaron a Odefsey, y 16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los que permanecieron en FTC/RPV/TDF. En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">366</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1160 el cambio medio desde el inicio en el recuento de las células CD4+ en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 fue de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en pacientes que se cambiaron a Odefsey, y 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">en los que permanecieron en EFV/FTC/TDF.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos infectados por el VIH</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">1 con insuficiencia renal leve o moderada</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0112, se evaluaron la eficacia y la seguridad del comprimido de CDF de E/C/F/TAF en un estudio clínico abierto de 242</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 virológicamente suprimidos con insuficiencia renal leve o moderada (TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt">: 30</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">69</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La media de la edad fue de 58</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">añ</span><span style="font-family:Times New Roman; font-size:11pt">os (rango 24</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">82), con 63</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes (26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">65</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años. El 79</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran hombres, el 63</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% blancos, el 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% negros y el 14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% asiáticos. El 35% de los pacientes estaban en una pauta de tratamiento que no contenía tenofovir disoproxilo fumarato. La mediana de la TFG</span><span style="font-family:Times New Roman; font-size:11pt">e</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt">basal fue de 56</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min, y el 33</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de los pacientes tenía una TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt">de 30 a 49</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min. La media del recuento basal de células CD4+ fue de 664</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 126</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.813).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">144, el 83,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (197/237</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes) mantuvo un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml después de cambiar a un comprimido de CDF de E/C/F/TAF.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1825, se evaluaron la eficacia y seguridad de E/C/F/TAF en un estudio clínico abierto, de un solo brazo en el que 55</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adultos infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 con nefropatía terminal (TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15 ml/min) en hemodiálisis crónica durante al menos 6 meses antes de cambiar al comprimido de CDF de E/C/F/TAF. Los pacientes estaban virológicamente suprimidos (ARN del VIH-1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50 copias/ml) durante al menos 6 meses antes del cambio.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La media de la edad fue de 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 23</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">64). El 76% eran hombres, el 82% negros y el 18% blancos. El 15% de los pacientes se identificaron como hispanos/latinos. La media del recuento basal de células</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4+ fue de 545</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 205</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1473). En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48, el 81,8% (45/55</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes) seguían con ARN del VIH-1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml tras cambiar a E/C/F/TAF. No hubo cambios clínicamente significativos en los resultados de laboratorio de los lípidos en los pacientes en ayunas que cambiaron de tratamiento.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes coinfectados por el VIH y el VHB</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio abierto GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1249 se evaluaron la eficacia y la seguridad de E/C/F/TAF en pacientes adultos coinfectados por el VIH-1 y hepatitis B crónica. Sesenta y nueve de los 72 pacientes recibieron una terapia antirretroviral previa que contenía TDF. Al comienzo del tratamiento con E/C/F/TAF, los 72 pacientes presentaron supresión del VIH (ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml) durante al menos 6 meses, con o sin supresión del ADN del VHB, y tenían la función hepática compensada. La media de edad era de 50 años (rango 28-67), el 92% de los pacientes eran varones, el 69% eran blancos, el 18%, negros y el 10%, asiáticos. La media del recuento basal de células CD4+ fue de 636</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango 263</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.498). El 86% de los pacientes (62/72) presentaron supresión del VHB (ADN del VHB &lt; 29 UI/ml) y el 42% (30/72) fueron HBeAg positivo en el momento basal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">De los pacientes que eran HBeAg positivo en el momento basal, 1/30 (3,3%) presentó seroconversión a anti-HBe en la semana 48. De los pacientes que eran HBsAg positivo en el momento basal, 3/70 (4,3%) presentaron seroconversión a anti-HBs en la semana 48.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 48 el 92% de los pacientes (66/72) mantenía un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml después de cambiar a E/C/F/TAF. El cambio medio del recuento de células CD4+ en la semana 48 con respecto al momento basal fue de</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2 células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">. El 92% de los pacientes (66/72) tenía ADN del VHB &lt; 29 UI/ml en la semana 48, usando un método de análisis “datos ausentes = fracaso”. De los 62</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con supresión del VHB en el momento</span><span style="font-family:Times New Roman; font-size:11pt">basal, la supresión se mantuvo en 59 y en 3 hubo ausencia de datos. De los 10 pacientes que no presentaron supresión del VHB en el momento basal (ADN del VHB ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">29</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">UI/ml), 7 pacientes lograron supresión, el ADN del VHB se mantuvo detectable en 2 pacientes</span><span style="font-family:Times New Roman; font-size:11pt">y hubo ausencia de datos en 1 paciente. Se observó normalización de la alanina aminotransferasa (ALT) en el 40% (4/10) de los sujetos cuyo valor de ALT excedía del límite superior de la normalidad (LSN) en el momento basal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Existen datos clínicos limitados sobre el uso de E/C/F/TAF en pacientes coinfectados por VIH/VHB sin tratamiento previo.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Cambios en las mediciones de la densidad mineral ósea</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En los estudios realizados con pacientes adultos sin tratamiento previo, E/C/F/TAF se asoció con reducciones má</span><span style="font-family:Times New Roman; font-size:11pt">s bajas de la densidad mineral ósea (DMO) comparado con E/C/F/TDF a lo largo de 144</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento, medida mediante análisis de absorciometría con rayos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">X de doble energía (DEXA) de la cadera (cambio medio: −0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span><a name="OLE_LINK23" id="OLE_LINK23"></a><a name="OLE_LINK24" id="OLE_LINK24"><span style="font-family:Times New Roman; font-size:11pt">comparado con</span></a><span style="font-family:Times New Roman; font-size:11pt">−3,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001) y de la columna lumbar (cambio medio: −0,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% comparado con −3,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron ligeras mejorías en la DMO, 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas después de cambiar a E/C/F/TAF en comparación con el mantenimiento de la pauta que contiene tenofovir disoproxilo fumarato.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En los estudios con Odefsey con pacientes adultos virológicamente suprimidos se observaron aumentos en la DMO a las 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas después de cambiarse a Odefsey con cambios mínimos en cadera en los que permanecieron con FTC/RPV/TDF o EFV/FTC/TDF (cambio medio 1,6% para Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,6% para FTC/RPV/TDF, p&lt;0,001; 1,8% para Odefsey</span><span style="font-family:TimesNewRomanPSMT; font-size:11pt">vs</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,6% para EFV/FTC/TDF, p&lt;0,001) y columna vertebral (cambio medio 2,0% para Odefsey</span><span style="font-family:TimesNewRomanPSMT; font-size:11pt">vs</span><span style="font-family:Times New Roman; font-size:11pt">-0,3% para FTC/RPV/TDF, p&lt;0,001; 1,7% para Odefsey</span><span style="font-family:TimesNewRomanPSMT; font-size:11pt">vs</span><span style="font-family:Times New Roman; font-size:11pt">0,1% para EFV/FTC/TDF, p&lt;0,001).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Cambios en las mediciones de la función renal</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En los estudios realizados con pacientes adultos sin tratamiento previo, E/C/F/TAF se asoció con un menor impacto sobre los parámetros de seguridad renal (medidos después de 144</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento por la TFGe</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">CG</span><span style="font-family:Times New Roman; font-size:11pt">y el cociente proteína/creatinina [CPC] en orina, y después de 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento por el cociente albúmina/creatinina [CAC] en orina) comparado con E/C/F/TDF. A lo largo de 144 semanas de tratamiento, ningún sujeto interrumpió el tratamiento con E/C/F/TAF debido a un acontecimiento adverso renal aparecido durante el tratamiento comparado con 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sujetos que interrumpieron el tratamiento con E/C/F/TDF (p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001). En estudios con pacientes adultos virológicamente suprimidos, durante 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento hubo cambios mínimos o reducciones en la albuminuria (CAC) en los pacientes que recibieron Odefsey comparado con aumentos desde el inicio en pacientes que permanecieron con FTC/RPV/TDF o EFV/FTC/TDF. Ver también sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pauta con emtricitabina</span></em><span style="font-family:Times New Roman; font-size:11pt"> </span><em><span style="font-family:Times New Roman; font-size:11pt;">+</span></em><span style="font-family:Times New Roman; font-size:11pt"> </span><em><span style="font-family:Times New Roman; font-size:11pt;">tenofovir alafenamida</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio GS-US-292-0106, se evaluó la eficacia, seguridad y farmacocinética del comprimido de CDF de E/C/F/TAF en un estudio abierto de 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adolescentes infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, sin tratamiento previo. Los pacientes tenían una media de edad de 15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años (rango 12</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">17), el 56</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran mujeres, el 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% asiáticos y el 88</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% negros. En el momento basal, la mediana del ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 plasmático fue de 4,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">log</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml, la mediana del recuento de células</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4+ fue de 456</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">(rango de 95 a 1.110) y la mediana de CD4+% fue del 23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (rango 7</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">45). En conjunto, el 22</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% tenía un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 plasmático basal &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">A las 48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, el 92</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (46/50) alcanzaron un ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml, de forma similar a las tasas de respuesta en los estudios con adultos infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 sin tratamiento previo. No se detectaron resistencias emergentes a E/C/F/TAF hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pauta que contiene rilpivirina</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio TMC278-C213, un estudio abierto de un solo brazo en fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">II en pacientes pediátricos infectados por VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 sin tratamiento antirretroviral previo, de 12 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad y con un peso mínimo de 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg, se evaluó la farmacocinética, seguridad, tolerabilidad y eficacia de 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de rilpivirina una vez al día en combinación con una PA seleccionada por el investigador que contenía dos ITIAN. La mediana de la duración de la exposición de los pacientes fue de 63,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Treinta y seis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes tenían una mediana de edad de 14,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años y el 55,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% eran mujeres, el 88,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">negros y el 11,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% asiáticos. La mediana del ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 plasmático basal fue de 4,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">log</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml y la mediana del recuento basal de células</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4+ fue de 414</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">células/mm</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">. La proporción de pacientes con ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml en la semana 48 (TLOVR) fue 72,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (26/36). La combinación de ITIAN utilizada con mayor frecuencia junto con rilpivirina fue FTC/TDF (24 sujetos [66,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%]).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La proporción de pacientes con respuesta fue mayor en los sujetos con una carga viral</span><span style="font-family:Times New Roman; font-size:11pt">basal ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (78,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 22/28) en comparación con aquellos con una carga viral basal&gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml (50,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 4/8). La proporción de fracasos virológicos fue de 22,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (8/36).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La Agencia Europea de Medicamentos ha concedido al titular un ap</span><span style="font-family:Times New Roman; font-size:11pt">lazamiento para presentar los resultados de los estudios realizados con Odefsey en uno o más grupos de la población pediátrica en tratamiento para la infección por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2 para consultar la información sobre el uso en la población pediátrica).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina (uno de los componentes de Odefsey) en combinación con una pauta de tratamiento de base se evaluó en el estudio TMC114HIV3015 en 19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mujeres embarazadas durante el 2º y el 3</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">er</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">trimestre y en el posparto. Los datos farmacocinéticos demuestran que la exposición total (AUC) a rilpivirina como parte de una pauta de tratamiento antirretroviral fue aproximadamente un 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% inferior durante el embarazo en comparación con el posparto (6-12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas). Por lo general, la respuesta virológica se mantuvo durante todo el estudio: de las 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes que finalizaron el estudio, 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes presentaron supresión al final del estudio; en las otras 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes se observó un aumento de la carga viral solo en el posparto, debido, al menos en 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pa</span><span style="font-family:Times New Roman; font-size:11pt">ciente, a una adherencia supuestamente deficiente. No se produjo ninguna transmisión maternofilial en los 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">lactantes nacidos de las madres que finalizaron el estudio y cuyo estado de VIH estaba disponible. Rilpivirina se toleró bien durante el embarazo y el posparto. No se produjeron nuevos hallazgos de seguridad en comparación con el perfil de seguridad conocido de rilpivirina en los adultos infectados por el VIH-1 (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2, 4.4 y 5.2).</span></p></div></text></section><section id="15e8f0b6-9afe-4449-a3f9-b3d17341fb82"><title value="5.2. Propiedades farmacocinéticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029827" /><display value="Propiedades farmacocinéticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Absorción</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Odefsey: Las exposiciones a emtricitabina y tenofovir alafenamida fueron bioequivalentes cuando se comparó un comprimido recubierto con película de Odefsey 200/25/25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg con un comprimido de combinación de dosis fija de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (150/150/200/10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) después de la administración de una dosis única a sujetos sanos (</span><span style="font-family:Times New Roman; font-size:11pt">n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">82) en condiciones de ingesta de alimentos. Las exposiciones a rilpivirina fueron bioequivalentes cuando se comparó Odefsey 200/25/25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg con un comprimido recubierto con película de rilpivirina (en forma de hidrocloruro) de 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg después de la administración de una dosis única a sujetos sanos (</span><span style="font-family:Times New Roman; font-size:11pt">n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">95) en condiciones de ingesta de alimentos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Emtricitabina se absorbe de forma rápida y extensa después de la administración oral con unas concentraciones plasmáticas máximas de 1 a 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de la dosis. Después de la administración oral de dosis múltiples de emtricitabina a 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sujetos infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, el (media</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">±</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">DE) área bajo la curva de la concentración plasmática frente al tiempo durante un intervalo de dosificación de 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas (AUC) fue de 10,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">±</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µg•h/ml. La media de la concentración plasmática valle en estado estacionario a las 24 horas de la administración de la dosis fue igual o mayor que la media del valor</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">del IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">90</span><span style="font-family:Times New Roman; font-size:11pt">para la actividad anti-VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1. La biodisponibilidad absoluta de emtricitabina a partir de cápsulas duras de 200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg se estimó en el 93</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%. La exposición sistémica a emtricitabina no se vio afectada cuando emtricitabina se administró con alimentos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Después de la administración oral, la concentración plasmática máxima de rilpivirina se logra generalmente en 4 a 5 horas. La biodisponibilidad absoluta de rilpivirina se desconoce. En relación a las condiciones en ayunas, la administración de Odefsey con alimentos a sujetos adultos sanos dio lugar a un aumento de la exposición a rilpivirina (AUC) de un 13</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">72</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida se absorbe de forma rápida después de la administración oral, alcanzándose unas concentraciones plasmáticas máximas a los 15 a 45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">minutos después de la dosis. En relación a las condiciones en ayunas, la administración de Odefsey con alimentos a sujetos adultos sanos dio lugar a un aumento de la exposición a tenofovir alafenamida (AUC) de un 45</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">53</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se recomienda que Odefsey se tome con alimentos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Distribución</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La unión</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">de emtricitabina a proteínas plasmáticas fue &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 % y resultó independiente de la concentración en el rango de 0,02</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">a</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µg/ml.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La unión</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">de ri</span><span style="font-family:Times New Roman; font-size:11pt">lpivirina a las proteínas plasmáticas es aproximadamente del 99,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, principalmente a la albúmina.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La unión</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">de tenofovir a proteínas plasmáticas es &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,7 % y es independiente de la concentración en el rango de 0,01</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μg/ml. La unión</span><em><span style="font-family:Times New Roman; font-size:11pt;">ex</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">de t</span><span style="font-family:Times New Roman; font-size:11pt">enofovir alafenamida a proteínas plasmáticas en las muestras recogidas durante los estudios clínicos fue de aproximadamente el 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Biotransformación</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La biotransformación de emtricitabina comprende la oxidación del radical tiólico para dar los diastereómeros 3'</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">sulfóxido (aproximadamente el</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis), y la conjugación con el ácido glucurónico para formar el 2'</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">O</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">glucurónido (aproximadamente el</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis). Emtricitabina no inhibió</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">el metabolismo de medicamentos mediado por cualquiera de las principales isoformas CYP humanas implicadas en la biotransformación de medicamentos. Además, emtricitabina tampoco inhibió la uridina-5'-difosfoglucuroniltransferasa (UGT), enzima responsable de la glucuronidación.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los experimentos</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">indican que rilpivirina hidrocloruro sufre principalmente metabolismo oxidativo mediado por el sistema CYP3A.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">El metabolismo es la ruta de eliminación principal de tenofovir alafenamida en los seres humanos, suponiendo &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de una dosis oral. Los estudios</span><em><span style="font-family:Times New Roman; font-size:11pt;">in</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">han mostrado que tenofovir alafenamida se metaboliza a tenofovir (metabolito principal) por medio de la catepsina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">A en las PBMC (incluyendo linfocitos y otras células diana del VIH) y los macrófagos y por medio de la carboxilesterasa</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 en los hepatocitos.</span><em><span style="font-family:Times New Roman; font-size:11pt;">In</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">, tenofovir alafenamida se hidroliza en las células para formar tenofovir (metabolito principal), que se fosforila al metabolito activo tenofovir difosfato. En los estudios clínicos humanos, una dosis oral de 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de tenofovir alafenamida administrado con emtricitabina, cobicistat y elvitegravir dio lugar a unas concentraciones de tenofovir difosfato más de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces superiores en las PBMC y más del</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% inferiores a las concentraciones de tenofovir en plasma en comparación con una dosis oral de 245</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de tenofovir disoproxilo (en forma de fumarato) administrado con emtricitabina, cobicistat y elvitegravir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">In</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">, tenofovir alafenamida no se metaboliza por CYP1A2, CYP2C8, CYP2C9, CYP2C19 o CYP2D6. Tenofovir alafenamida se metaboliza mínimamente por CYP3A4. Cuando se administra de forma concomitante con el conocido inductor moderado de CYP3A efavirenz, la exposición a tenofovir alafenamida no se ve afectada significativamente. Después de la administración de tenofovir alafenamida, la radiactividad [</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">14</span><span style="font-family:Times New Roman; font-size:11pt">C] en plasma mostró un perfil dependiente del tiempo, siendo tenofovir alafenamida la especie más abundante en las primeras horas iniciales y el ácido úrico en el periodo restante.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Eliminación</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Emtricitabina se excreta fundamentalmente por el riñón y la dosis se recupera por completo en la orina (aproximadamente</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">86</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) y en las heces (aproximadamente</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%). El 13% de la dosis de emtricitabina se recoge en la orina en forma de tres metabolitos. El aclaramiento sistémico de emtricitabina alcanzó un promedio de 307</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min. Tras la administración oral, la semivida de eliminación de emtricitabina es de aproximadamente 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La semivida de eliminación terminal de rilpivirina es de aproximadamente 45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas. Tras la administración oral de una sola dosis de [</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">14</span><span style="font-family:Times New Roman; font-size:11pt">C]</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">rilpivirina, un promedio del 85</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y el 6,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la radioactividad se recuperaron en las heces y en la orina, respectivamente. En las heces, rilpivirina sin metabolizar representó un promedio del 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis administrada. Solamente se detectaron cantidades mínimas de rilpivirina sin metabolizar (&lt;1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis) en la orina.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La excreción renal de tenofovir alafenamida intacto es una ruta menor, siendo &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis eliminada por la orina. Tenofovir alafenamida se elimina principalmente después de la metabolización a tenofovir. Tenofovir se elimina del organismo por vía renal por filtración glomerular y secreción tubular activa.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Farmacocinética en poblaciones especiales</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Edad, sexo y raza</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha identificado ninguna diferencia farmacocinética clínicamente relevante en relación con la edad, el sexo o la raza para emtricitabina, rilpivirina o tenofovir alafenamida.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La farmacocinética de rilpivirina en pacientes pediátricos infectados por VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 sin tratamiento antiretroviral previo de 12 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad que recibieron 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de rilpivirina una vez al día fue comparable a la de adultos infectados por VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 sin tratamiento previo y que recibieron 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de rilpivirina una vez al día. El peso corporal no afectó a la farmacocinética de rilpivirina en pacientes pediátricos en el estudio C213 (33 a 93</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg), de modo similar a lo observado en los adultos. La farmacocinética de rilpivirina en pacientes pediátricos &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad se está investigando.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Las exposiciones a emtricitabina y tenofovir alafenamida administrados con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat alcanzadas en 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos de 12 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad fueron similares a las exposiciones alcanzadas en adultos sin tratamiento previo (Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">6: Farmacocinética de emtricitabina y tenofovir alafenamida en adolescentes y adultos sin tratamiento antirretroviral</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><thead><tr><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:190.2pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Adolescentes</span></strong></p></td><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Adultos</span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Emtricitabina +</span></strong><span style="font-family:Times New Roman; font-size:10pt"> </span><strong><span style="font-family:Times New Roman; font-size:10pt;">tenofovir alafenamida</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:190.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Emtricitabina +</span></strong><span style="font-family:Times New Roman; font-size:10pt"> </span><strong><span style="font-family:Times New Roman; font-size:10pt;">tenofovir alafenamida</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">FTC</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">TAF</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">TFV</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">FTC</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">TAF</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">TFV</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">c</span></p></td></tr></thead><tbody><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">AUC</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">tau</span><span style="font-family:Times New Roman; font-size:10pt">(ng•h/ml)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">14.424,4 (23,9)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">242,8 (57,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">275,8 (18,4)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">11.714,1 (16,6)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">206,4 (71,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">292,6 (27,4)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">max</span><span style="font-family:Times New Roman; font-size:10pt">(ng/ml)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2.265,0 (22,5)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">121,7 (46,2)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">14,6 (20,0)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2.056,3 (20,2)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">162,2 (51,1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">15,2 (26,1)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">C</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">tau</span><span style="font-family:Times New Roman; font-size:10pt">(ng/ml)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">102,4 (38,9)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">N/A</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">10,0 (19,6)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">95,2 (46,7)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">N/A</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">10,6 (28,5)</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:76.85pt; border:none">
                                        </td>
                                        <td style="width:68.35pt; border:none">
                                        </td>
                                        <td style="width:55.45pt; border:none">
                                        </td>
                                        <td style="width:55.45pt; border:none">
                                        </td>
                                        <td style="width:68.6pt; border:none">
                                        </td>
                                        <td style="width:55.65pt; border:none">
                                        </td>
                                        <td style="width:55.65pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:1pt 0pt 0pt; text-indent:-14.4pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.4pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">FTC</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">emtricitabina; TAF</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">tenofovir alafenamida; TFV</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">tenofovir, N/A</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">no aplicable</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">Los datos se presentan como medias (%CV).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">a</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">24</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">adolescentes (GS</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">US</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">292</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">0106); n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">19</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">adultos (GS</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">US</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">292</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">0102).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">b</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">23</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">adolescentes (GS</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">US</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">292</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">0106, análisis PK poblacional).</span></p><p style="margin:0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:9pt" ><span style="font-family:Times New Roman; font-size:9pt">c</span><span style="font-family:Times New Roman; font-size:9pt">             </span><span style="font-family:Times New Roman; font-size:9pt">n</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">=</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">539 (TAF) u 841 (TFV) adultos (GS</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">US</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">292</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">0111 y GS</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">US</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">292</span><span style="font-family:Times New Roman; font-size:9pt">‑</span><span style="font-family:Times New Roman; font-size:9pt">0104, análisis PK poblacional).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observaron diferencias clínicamente relevantes en la farmacocinética de tenofovir alafenamida ni de tenofovir entre los sujetos sanos ni en los pacientes con insuficiencia renal grave (ClCr</span><span style="font-family:Times New Roman; font-size:11pt">estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15 ml/min y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) en un estudio de fase I de tenofovir alafenamida. En otro estudio de fase I aparte de emtricitabina sola, la exposición sistémica media a emtricitabina fue mayor en pacientes con insuficiencia renal grave (ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) (33,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μg•h/ml) que en sujetos con función renal normal (11,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μg•h/ml). No se ha establecido la seguridad de emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en pacientes con insuficiencia renal grave (ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estu</span><span style="font-family:Times New Roman; font-size:11pt">dio GS</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">US</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1825, la exposición a emtricitabina y tenofovir en 12 pacientes con nefropatía terminal (ClCr estimado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ml/min) en hemodiálisis crónica que recibieron emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">cobicistat como comprimido de combinación a dosis fija (E/C/F/TAF) fue significativamente mayor que en pacientes con función renal normal. No se observaron diferencias clínicamente relevantes en la farmacocinética de tenofovir alafenamida en pacientes con nefropatía terminal en hemodiálisis crónica, en comparación con los sujetos con función renal normal. No se identificaron problemas de seguridad nuevos en los pacientes con nefropatía terminal en hemodiálisis crónica tratados con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir alafenamida en combinación con elvitegravir + cobicistat como comprimido de combinación a dosis fija (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">No se dispone de datos farmacocinéticos de emtricitabina ni de tenofovir alafenamida en pacientes con nefropatía terminal (ClCr estimado</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">&lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">15</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">ml/min) que no reciben hemodiálisis crónica. No se ha establecido la seguridad de emtricitabina y tenofovir alafenamida en estos pacientes.</span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha estudiado la farmacocinética de rilpivirina en pacientes con insuficiencia renal. La eliminación renal de rilpivirina es insignificante. En pacientes con insuficiencia renal grave o nefropatía en etapa terminal, las concentraciones plasmáticas se pueden incrementar debido a la alteración de la absorción del fármaco, la distribución y/o el metabolismo secundario a la disfunción renal. Dado que rilpivirina se une en gran medida a proteínas plasmáticas, es improbable que se elimine de forma significativa mediante hemodiálisis o diálisis peritoneal (ver sección 4.9).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia hepática</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha estudiado la farmacocinética de emtricitabina en pacientes con diversos grados de insuficiencia hepática; sin embargo emtricitabina no sufre un metabolismo significativo a través de las enzimas hepáticas, por lo que la repercusión de la insuficiencia hepática debería ser escasa.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Rilpivirina hidrocloruro se metaboliza y elimina principalmente por el hígado. En un estudio comparativo de 8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con insuficiencia hepática leve (clase A de Child-Pugh) con 8 controles emparejados y 8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con insuficiencia hepática moderada (clase B de Child-Pugh) con 8 controles emparejados, la exposición tras dosis múltiples de rilpivirina fue un 47</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% mayor en los pacientes con insuficiencia hepática leve y un 5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% mayor en pacientes con insuficiencia hepática moderada. Sin embargo, no se puede descartar que la exposición a rilpivirina farmacológicamente activa, libre, esté significativamente aumentada en la insuficiencia moderada. Rilpivirina no se ha estudiado en pacientes con insuficiencia hepática grave (clase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C de Child-Pugh) (ver sección 4.2).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observaron cambios clínicamente relevantes en la farmacocinética de tenofovir alafenamida o su metabolito tenofovir en los pacientes con insuficiencia hepática leve o moderada.</span><span style="font-family:Times New Roman; font-size:11pt">En pacientes con insuficiencia hepática grave, las concentraciones plasmáticas totales de tenofovir alafenamida y tenofovir son más bajas que las observadas en sujetos con función hepática normal. Cuando se corrigen por la unión a proteínas, las concentraciones plasmáticas de tenofovir alafenamida no unido a proteínas (libre) son similares</span><span style="font-family:Times New Roman; font-size:11pt">en pacientes</span><span style="font-family:Times New Roman; font-size:11pt">con insuficiencia hepática grave y</span><span style="font-family:Times New Roman; font-size:11pt">en sujetos</span><span style="font-family:Times New Roman; font-size:11pt">con función hepática normal</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Infección concomitante por el virus de la hepatitis</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">B y/o de la hepatitis</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">C</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha evaluado por completo la farmacocinética de emtricitabina, rilpivirina y tenofovir alafenamida en los pacientes con infección concomitante por el virus de la hepatitis B y/o C.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Embarazo y posparto</span></em></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Tras tomar rilpivirina 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día como parte de una pauta de tratamiento antirretroviral, la exposición total de rilpivirina fue inferior durante el embarazo (similar para el 2º y el 3</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">er</span><span style="font-family:Times New Roman; font-size:11pt">trimestre) en comparación con el posparto. La disminución en la exposición a la fracción libre de rilpivirina (es decir, activa) durante el embarazo en comparación con el posparto fue menos pronunciada que para la exposición total de rilpivirina.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En las mujeres que recibieron rilpivirina 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día durante el 2º trimestre del embarazo, la media de los valores intraindividuales C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">, AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24h</span><span style="font-family:Times New Roman; font-size:11pt">y C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">mín</span><span style="font-family:Times New Roman; font-size:11pt">correspondientes a rilpivirina total fueron un 21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 29</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% inferiores, respectivamente, en comparación con el posparto; durante el 3</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">er</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">trimestre del embarazo, los valores de C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">, AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24h</span><span style="font-family:Times New Roman; font-size:11pt">y C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">mín</span><span style="font-family:Times New Roman; font-size:11pt">fueron un 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 31</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 42</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% inferiores, respectivamente, en comparación con el posparto.</span></p></div></text></section><section id="7cbf1dc5-f2c4-4f32-8979-9d1d70b3cdf1"><title value="5.3. Datos preclínicos sobre seguridad" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029834" /><display value="Datos preclínicos sobre seguridad" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los datos de los estudios no clínicos no muestran riesgos especiales para los seres humanos según los estudios convencionales de farmacología de seguridad, toxicidad a dosis repetidas, genotoxicidad, potencial carcinogénico</span><strong><span style="font-family:Times New Roman; font-size:11pt;">,</span></strong><span style="font-family:Times New Roman; font-size:11pt">toxicidad para la reproducción y el desarrollo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los datos de los estudios no clínicos de rilpivirina hidrocloruro no muestran riesgos especiales para los seres humanos según los estudios de farmacología de seguridad, distribución del fármaco, genotoxicidad, potencial carcinogénico y toxicidad para la reproducción y el desarrollo. Se observó en roedores toxicidad hepática asociada a la inducción de enzimas hepáticas. En perros se observaron efectos similares a colestasis.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Estudios de carcinogenicidad en ratones y ratas con rilpivirina revelaron un potencial tumorigénico específico para estas especies, pero no se consideran de relevancia para los seres humanos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los estudios no clínicos de tenofovir alafenamida en ratas y perros mostraron los huesos y el riñón como los órganos diana primarios para la toxicidad. La toxicidad ósea se observó en forma de reducción de la densidad mineral ósea en ratas y perros a unas exposiciones a tenofovir al menos cuatro veces superiores a las esperadas después de la administración de Odefsey. Hubo una mínima infiltración de histiocitos presente en el ojo de perros a exposiciones a tenofovir alafenamida y tenofovir aproximadamente 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces superiores, respectivamente, a las esperadas después de la administración de Odefsey.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Tenofovir alafenamida no fue mutagénico ni clastogénico en los estudios convencionales de genotoxicidad.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Dado que existe una menor exposición a tenofovir en ratas y ratones después de la administración de tenofovir alafenamida en comparación con tenofovir disoproxilo fumarato, los estudios de carcinogenicidad y un estudio peri-posnatal en ratas fueron realizados solamente con tenofovir disoproxilo fumarato. Los estudios convencionales de potencial carcinogénico y toxicidad para la reproducción y el desarrollo no mostraron riesgos especiales para los seres humanos. Los estudios de toxicidad para la reproducción en ratas y conejos no mostraron ningún efecto en los parámetros de apareamiento, fertilidad, embarazo o parámetros fetales. No obstante, tenofovir disoproxilo fumarato redujo el índice de viabilidad y peso de las crías en un estudio</span><span style="font-family:TimesNewRomanPSMT; font-size:11pt">peri-posnatal de toxicidad a dosis tóxicas para la madre</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="cb514c3b-ef5e-43e4-ab95-0f92bd185259"><title value="6. Datos farmacéuticos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029836" /><display value="Datos farmacéuticos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="2106d640-d0e3-4189-bb21-968b63aab9fc"><title value="6.1. Lista de excipientes" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029837" /><display value="Lista de excipientes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Núcleo del comprimido</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Croscarmelosa sódica</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Lactosa (en forma de monohidrato)</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Estearato magnésico</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Celulosa microcristalina</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Polisorbato</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Povidona</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Cubierta pelicular</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Macrogol</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Alcohol polivinílico</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Talco</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Dióxido de titanio (E171)</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Óxido de hierro negro (E172)</span></p></div></text></section><section id="17596354-d72a-4573-b9a0-21491a1e5ee8"><title value="6.2. Incompatibilidades" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029838" /><display value="Incompatibilidades" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No procede.</span></p></div></text></section><section id="da9a222c-6bbe-4a1d-be61-ea9bb72e2cb6"><title value="6.3. Periodo de validez" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029839" /><display value="Periodo de validez" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años.</span></p></div></text></section><section id="8f970a4b-7e88-4c13-bee2-f2cd3347849d"><title value="6.4. Precauciones especiales de conservación" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029840" /><display value="Precauciones especiales de conservación" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Conservar en el embalaje original para protegerlo de la humedad. Mantener el frasco perfectamente cerrado.</span></p></div></text></section><section id="9ea15d8e-9b9f-488d-b548-2cd4f0c4cc90"><title value="6.5. Naturaleza y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029841" /><display value="Naturaleza y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Frasco de polietileno de alta densidad HDPE, con una cápsula de cierre de seguridad de polipropileno y rosca continua, a prueba de niños, recubierto con una funda de lámina de aluminio activado por inducción que contiene 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos recubiertos con película. Cada frasco contiene un desecante de gel de sílice y un relleno de poliéster.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Este medicamento está disponible en envases de 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frasco de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos recubiertos con película y en envases de 90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frascos de 30)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos recubiertos con película.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p></div></text></section><section id="d5cc476d-8591-4999-a0cd-f392f227c296"><title value="6.6. Precauciones especiales de eliminación y otras manipulaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029842" /><display value="Precauciones especiales de eliminación y otras manipulaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él se realizará de acuerdo con la normativa local.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="86fcdcc7-936e-4f2e-89f7-b6849599763a"><title value="7. Titular de la autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029844" /><display value="Titular de la autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Carrigtohill</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">County Cork, T45 DP77</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Ιrlanda</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="f535d6da-eeb2-4cfb-bed5-08504332b7ab"><title value="8. Número(s) de autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029845" /><display value="Número(s) de autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/16/1112/001</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/16/1112/002</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="4ac8dcd1-5aaa-4bd2-93cc-22295fd0f98c"><title value="9. Fecha de la primera autorización/ renovación de la autorización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029846" /><display value="Fecha de la primera autorización/ renovación de la autorización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Fecha de la primera autorización: 21/junio/2016</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="827849dd-7ed2-4666-a1d2-c4855c11a094"><title value="10. Fecha de la revisión del texto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029847" /><display value="Fecha de la revisión del texto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">{MM/AAAA}</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos</span><span style="font-family:Times New Roman; font-size:11pt">http://www.ema.europa.eu.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section></Composition></resource></entry></Bundle></resource></entry><entry><fullUrl value="2a224e09-dff9-4236-917b-f7381d497789" /><resource><Bundle><id value="2a224e09-dff9-4236-917b-f7381d497789" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="2a224e09-dff9-4236-917b-f7381d497789" /></identifier><type value="document" /><timestamp value="2024-12-04T17:54:30.5616178+01:00" /><entry><fullUrl value="2a224e09-dff9-4236-917b-f7381d497789" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155538" /><display value="Prospecto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-04" /><author><reference value="systemUser" /></author><title value="Prospecto" /><section><title value="Prospecto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029894" /><display value="Prospecto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Prospecto: información para el usuario</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt; background-color:#ffffff"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Odefsey 200</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg/25</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg/</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">25</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">comprimidos recubiertos con película</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">emtricitabina/rilpivirina/tenofovir alafenamida</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="23" height="19" alt="BT_1000x858px" /><span style="font-family:Times New Roman; font-size:11pt">Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad. Puede contribuir comunicando los efectos adversos que pudiera usted tener. La parte final de la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 incluye información sobre cómo comunicar estos efectos adversos.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene información importante para usted.</span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 28.35pt; text-indent:-28.35pt; font-family:serif; font-size:11pt; list-style-position:inside"><span style="font:7.0pt Times New Roman">     </span><span style="font-family:Times New Roman; font-size:11pt">Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li style="margin:0pt 0pt 0pt 28.35pt; text-indent:-28.35pt; font-family:serif; font-size:11pt; list-style-position:inside"><span style="font:7.0pt Times New Roman">     </span><span style="font-family:Times New Roman; font-size:11pt">Si tiene alguna duda, consulte a su médico o farmacéutico.</span></li></ul><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">-</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Este medicamento se le ha recetado solamente a usted, y no debe dárselo a otras personas aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 28.35pt; text-indent:-28.35pt; font-family:serif; font-size:11pt; list-style-position:inside"><span style="font:7.0pt Times New Roman">     </span><span style="font-family:Times New Roman; font-size:11pt">Si experimenta efectos adversos, consulte a su médico o farmacéutico,</span><span style="font-family:Times New Roman; font-size:11pt">incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Contenido del prospecto</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">1.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Qué es</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">y para qué se utiliza</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">2.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Qué necesita saber antes de empezar a tomar</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">3.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Cómo tomar</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">4.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Posibles efectos adversos</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">5.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Conservación de</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">6.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Contenido del envase e información adicional</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text><section id="2b8855d5-2a10-4e24-b13a-105b435cda3a"><title value="1. Qué es Odefsey y para qué se utiliza" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029895" /><display value="Qué es &quot;X&quot; y para qué se utiliza" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-1.35pt; line-height:115%; padding-left:1.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey es un medicamento antiviral utilizado para tratar la infección por el</span><strong><span style="font-family:Times New Roman; font-size:11pt;">virus de la inmunodeficiencia humana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">(VIH).</span></strong><span style="font-family:Times New Roman; font-size:11pt">Es un solo comprimido que contiene una combinación de tres principios activos:</span><strong><span style="font-family:Times New Roman; font-size:11pt;">emtricitabina, rilpivirina y tenofovir alafenamida</span></strong><span style="font-family:Times New Roman; font-size:11pt">. Cada uno de estos principios activos actúa interfiriendo con una enzima llamada «transcriptasa inversa», que es esencial para que el virus VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 se multiplique.</span></p><p style="margin:0pt; text-indent:-1.35pt; line-height:115%; padding-left:1.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-1.35pt; line-height:115%; padding-left:1.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey reduce la cantidad de VIH presente en el organismo. Esto mejora el sistema inmunitario y disminuye el riesgo de desarrollar enfermedades asociadas con la infección por el VIH.</span></p><p style="margin:0pt; text-indent:-1.35pt; line-height:115%; padding-left:1.35pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-1.35pt; line-height:115%; padding-left:1.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey se utiliza en adultos y adolescentes de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad o mayores con un peso de al menos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="f6cb5fe5-ed7b-4b97-90a8-e20ae6d919fe"><title value="2. Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; Qué necesita saber antes de empezar a tomar Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029896" /><display value="Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="4c7cb191-085c-487a-a66e-9ce5dbe05e1d"><title value="No tomeOdefsey:" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="No tomeOdefsey:" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">si es alérgico a emtricitabina, rilpivirina, tenofovir alafenamida</span></strong><span style="font-family:Times New Roman; font-size:11pt">o a alguno de los demás componentes de este medicamento (incluidos en la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6).</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">si está tomando alguno de los siguientes medicamentos:</span></strong></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">carbamazepina, oxcarbazepina, fenobarbital y fenitoína</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para tratar la epilepsia y prevenir las convulsiones)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">rifabutina, rifampicina y</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">rifapentina</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para tratar algunas infecciones bacterianas como la tuberculosis)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">omeprazol, dexlansoprazol, lansoprazol, rabeprazol, pantoprazol y esomeprazol</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para prevenir y tratar úlceras de estómago, ardores y enfermedad por reflujo ácido)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">dexametasona</span></strong><span style="font-family:Times New Roman; font-size:11pt">(un corticosteroide utilizado para tratar la inflamación y suprimir el sistema inmunitario) cuando se toma por vía oral o inyectado (excepto como tratamiento de dosis única)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">productos que contienen hierba de San Juan</span></strong><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:11pt">, una planta medicinal utilizada para la depresión y la ansiedad)</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="1b451b2b-1724-4eed-975f-9f504c54873f"><title value="?Si se encuentra en alguna de estas circunstancias,no tome Odefsey y consulte a su médico inmediatamente." /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="?Si se encuentra en alguna de estas circunstancias,no tome Odefsey y consulte a su médico inmediatamente." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="931fb458-d03e-4396-bb96-95a9ab6cf689"><title value="Advertencias y precauciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029898" /><display value="Advertencias y precauciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tiene que permanecer bajo supervisión de su médico mientras esté tomando Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mientras esté tomando este medicamento</span><strong><span style="font-family:Times New Roman; font-size:11pt;">aún puede transmitir el VIH a los demás,</span></strong><span style="font-family:Times New Roman; font-size:11pt">aunque el tratamiento antirretroviral eficaz reduzca el riesgo. Consulte a su médico sobre qué precauciones son necesarias para no infectar a otras personas. Este medicamento no es una cura para la infección por el VIH. Mientras usted esté tomando</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">podrá seguir padeciendo infecciones u otras enfermedades asociadas con la infección por el VIH.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte a su médico antes de empezar a tomar Odefsey:</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene problemas hepáticos o antecedentes de enfermedad hepática, incluida hepatitis.</span></strong><span style="font-family:Times New Roman; font-size:11pt">Los pacientes con enfermedad hepática incluida hepatitis crónica</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C, tratados con antirretrovirales, tienen un riesgo mayor de complicaciones hepáticas graves y potencialmente mortales. Si padece infección por hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B, su médico considerará cuidadosamente la mejor pauta de tratamiento para usted.</span></li></ul><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si padece infección por hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B, los problemas hepáticos pueden empeorar después de interrumpir la administración de</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">. Es importante que no deje de tomar</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">sin hablar antes con su médico: ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3,</span><em><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">Odefsey</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está tomando cualquier medicamento que pueda causar un latido irregular del corazón</span><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">Torsades de Pointes</span></em><span style="font-family:Times New Roman; font-size:11pt">) potencialmente mortal.</span></li></ul><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Mientras esté tomando</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">Odefsey</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una vez que empiece a tomar</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">, esté atento a:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Signos de inflamación o infección</span></strong></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dolor articular, rigidez o problemas óseos</span></strong></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos síntomas, informe a su médico inmediatamente.</span></strong><span style="font-family:Times New Roman; font-size:11pt">Para más información, ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4,</span><em><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos</span></em><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es posible que en el futuro se puedan experimentar problemas renales si se toma Odefsey durante un periodo de tiempo prolongado.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="e8eb2a1c-b9a3-404e-b04d-97b8aa41fd9a"><title value="Niños y adolescentes" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029899" /><display value="Niños y adolescentes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="d574d330-7106-4298-8d31-b669826a3946"><title value="No administre este medicamento a niños de 11 años de edad o menores o que pesen menos de 35 kg. No se ha estudiado todavía el uso de Odefsey en niños de 11 años de edad o menores o que pesen menos de 35 kg." /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="No administre este medicamento a niños de 11 años de edad o menores o que pesen menos de 35 kg. No se ha estudiado todavía el uso de Odefsey en niños de 11 años de edad o menores o que pesen menos de 35 kg." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="3dffc914-8ba8-4e3e-bb0b-d78c54ee7c17"><title value="Otros medicamentos y Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029900" /><display value="Otros medicamentos y Odefsey" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Informe a su médico o farmacéutico si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento</span></strong><span style="font-family:Times New Roman; font-size:11pt">. Odefsey puede interaccionar con otros medicamentos. Como consecuencia, los niveles sanguíneos de Odefsey o de otros medicamentos pueden verse afectados. Esto puede impedir que sus medicamentos funcionen correctamente o empeorar sus posibles efectos adversos. En algunos casos, su médico puede tener que ajustar la dosis o comprobar sus concentraciones sanguíneas.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos que nunca deben tomarse con Odefsey:</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">carbamazepina, oxcarbazepina, fenobarbital y fenitoína</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para tratar la epilepsia y prevenir las convulsiones)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">rifabutina, rifampicina y</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">rifapentina</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para tratar algunas infecciones bacterianas como la tuberculosis)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">omeprazol, dexlansoprazol, lansoprazol, rabeprazol, pantoprazol y esomeprazol</span></strong><span style="font-family:Times New Roman; font-size:11pt">(utilizados para prevenir y tratar úlceras de estómago, ardores y enfermedad por reflujo ácido)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">dexametasona</span></strong><span style="font-family:Times New Roman; font-size:11pt">(un medicamento corticosteroide utilizado para tratar la inflamación y suprimir el sistema inmunitario) cuando se toma por vía oral o inyectado (excepto como tratamiento de dosis única)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">productos que contienen hierba de San Juan</span></strong><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">Hypericum perforatum</span></em><span style="font-family:Times New Roman; font-size:11pt">, una planta medicinal utilizada para la depresión y la ansiedad)</span></li></ul><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="18133d1b-66af-4008-bdce-c5bc4a96a498"><title value="?Si está tomando alguno de estos medicamentos,no tome Odefsey y consulte a su médico inmediatamente." /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="?Si está tomando alguno de estos medicamentos,no tome Odefsey y consulte a su médico inmediatamente." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Otros tipos de medicamentos:</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte con su médico si está tomando:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cualquier medicamento utilizado para tratar el VIH</span></strong></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cualquier medicamento que contenga:</span></strong></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">tenofovir</span><span style="font-family:Times New Roman; font-size:11pt">alafenamida</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">lamivudina</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">adefovir dipivoxil</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Antibióticos utilizados para tratar las infecciones bacterianas</span></strong><span style="font-family:Times New Roman; font-size:11pt">que contengan:</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">claritromicina</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">eritromicina</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Estos medicamentos pueden aumentar la cantidad de rilpivirina y tenofovir alafenamida (componentes de</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">) en la sangre. Su médico le administrará un medicamento diferente.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Antifúngicos utilizados para tratar las infecciones por hongos:</span></strong></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ketoconazol</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">fluconazol</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">itraconazol</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">posaconazol</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">voriconazol</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Estos medicamentos pueden aumentar la cantidad de rilpivirina y tenofovir alafenamida (componentes de Odefsey) en la sangre. Su médico le administrará un medicamento diferente.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos para las úlceras de estómago, acidez gástrica o reflujo ácido</span></strong><span style="font-family:Times New Roman; font-size:11pt">como:</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiácidos</span></strong><span style="font-family:Times New Roman; font-size:11pt">(hidróxido de aluminio/magnesio o carbonato cálcico)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antagonistas H</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span></strong><span style="font-family:Times New Roman; font-size:11pt">(famotidina, cimetidina, nizatidina o ranitidina)</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Estos medicamentos pueden disminuir los niveles de rilpivirina (un componente de Odefsey) en la sangre. Si usted está tomando uno de estos medicamentos su médico le administrará un medicamento diferente o le recomendará cómo y cuándo tomar este medicamento:</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si está tomando un antiácido,</span></strong><span style="font-family:Times New Roman; font-size:11pt">tómelo al menos 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de Odefsey.</span></li></ul><p style="margin:0pt 0pt 0pt 56.7pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si está tomando un antagonista H</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span></strong><span style="font-family:Times New Roman; font-size:11pt">, tómelo al menos 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de Odefsey. Los antagonistas H</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:11pt">sólo pueden tomarse una vez al día si toma Odefsey. Los antagonistas H</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:11pt">no se deben tomar en una pauta de dos veces al día. Hable con su médico para que le indique una pauta alternativa (ver Cómo tomar Odefsey).</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ciclosporina,</span></strong><span style="font-family:Times New Roman; font-size:11pt">un medicamento utilizado para reducir la actividad del sistema inmunitario del</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">organismo:</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento puede aumentar la cantidad de rilpivirina y tenofovir alafenamida (componentes de Odefsey) en la sangre. Su médico le administrará un medicamento diferente.</span></p><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Metadona,</span></strong><span style="font-family:Times New Roman; font-size:11pt">un medicamento utilizado para tratar la adicción a los opiáceos, ya que su médico puede tener que cambiar su dosis de metadona.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dabigatrán etexilato</span></strong><span style="font-family:Times New Roman; font-size:11pt">, un medicamento utilizado para tratar las enfermedades cardíacas, ya que su médico puede tener que controlar las concentraciones de este medicamento en su sangre.</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Consulte con su médico si está tomando alguno de estos medicamentos</span></strong><span style="font-family:Times New Roman; font-size:11pt">. No interrumpa su tratamiento sin consultar con su médico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="b519d33d-f047-41bf-97b7-32f9fac96190"><title value="Embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029902" /><display value="Embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está embarazada o en periodo de lactancia, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico antes de utilizar este medicamento.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Utilice un método eficaz de</span></strong><strong><span style="font-family:TimesNewRomanPS-BoldMT; font-size:11pt;">contracepción</span></strong><span style="font-family:Times New Roman; font-size:11pt">mientras esté tomando Odefsey.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte a su médico o farmacéutico antes de utilizar cualquier medicamento si está embarazada.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si usted ha tomado Odefsey durante su embarazo, su médico puede solicitar análisis de sangre periódicos y otras pruebas de diagnóstico para controlar el desarrollo de su hijo. En niños cuyas madres tomaron</span><span style="font-family:Times New Roman; font-size:11pt">inhibidores de transcriptasa inversa análogos de nucleósidos</span><span style="font-family:Times New Roman; font-size:11pt">(ITIAN) durante el embarazo, el beneficio de la protección frente al VIH fue mayor que el riesgo de que se produjeran efectos adversos.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No dé el pecho a su hijo durante el tratamiento con Odefsey</span></strong><span style="font-family:Times New Roman; font-size:11pt">. Esto se debe a que algunos de los principios activos de este medicamento pasan a la leche materna. Se recomienda que no dé el pecho para evitar que transmita el virus al niño a través de la leche materna.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="f7f7455a-a2e1-4614-83d4-17190bb3402f"><title value="Conducción y uso de máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029903" /><display value="Conducción y uso de máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No conduzca ni maneje máquinas si nota cansancio, tiene sueño o mareos después de tomar su medicamento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Odefsey contiene lactosa</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si su médico le ha indicado que padece una intolerancia a ciertos azúcares, consulte con él antes de tomar este medicamento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">Si se encuentra en alguna de estas circunstancias,</span><strong><span style="font-family:Times New Roman; font-size:11pt;">consulte a su médico antes de empezar a tomar Odefsey.</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="f1cfa7bb-4000-4c86-885d-110cb0d5ad77"><title value="3. Cómo tomar Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029905" /><display value="Cómo &quot;&lt;tomar&gt;&lt;usar&gt; X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico. En caso de duda, consulte de nuevo a su médico o farmacéutico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">La dosis recomendada es:</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adultos:</span></strong><span style="font-family:Times New Roman; font-size:11pt">un comprimido al día con alimentos</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adolescentes de 12</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">años de edad o mayores, que pesen al menos 35</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">kg:</span></strong><span style="font-family:Times New Roman; font-size:11pt">un comprimido al día con</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">alimentos</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No mastique, machaque ni divida el comprimido.</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si está tomando un antiácido</span></strong><span style="font-family:Times New Roman; font-size:11pt">, como hidróxido de aluminio/magnesio, o carbonato cálcico, tómelo al menos 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si está tomando un antagonista H</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span></strong><span style="font-family:Times New Roman; font-size:11pt">como famotidina, cimetidina, nizatidina o ranitidina, tómelo al menos 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas antes o al menos 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de Odefsey. Los antagonistas H</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:11pt">sólo pueden tomarse una vez al día si está tomando Odefsey. Los antagonistas H</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">2</span><span style="font-family:Times New Roman; font-size:11pt">no se deben tomar dos veces al día. Hable con su médico para que le indique una pauta alternativa.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si recibe diálisis</span></strong><span style="font-family:Times New Roman; font-size:11pt">, tome la dosis diaria de Odefsey una vez finalizada la diálisis.</span></p></div></text><section id="005f0adf-c2dc-4199-acf9-d7485a8bf175"><title value="Si toma más Odefsey del que debe" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029907" /><display value="Si toma más Odefsey del que debe" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si toma accidentalmente más de la dosis recomendada de Odefsey, puede correr mayor riesgo de experimentar posibles efectos adversos con este medicamento (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4,</span><em><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte inmediatamente a su médico o acuda al servicio de urgencias más cercano. Guarde o lleve consigo el frasco de comprimidos para que pueda describir fácilmente qué ha tomado.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="15868bff-79c3-4c3c-81be-5999455bdeff"><title value="Si olvidó tomar Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029908" /><display value="Si olvidó tomar Odefsey" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante que no olvide una dosis de Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si olvida una dosis:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si se da cuenta en las 12</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">horas</span></strong><span style="font-family:Times New Roman; font-size:11pt">posteriores a la hora a la que normalmente toma</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">, debe tomar el comprimido tan pronto como sea posible. Tome el comprimido siempre con alimentos. Luego tome la dosis siguiente de la forma habitual.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si se da cuenta 12</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">horas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">o más</span></strong><span style="font-family:Times New Roman; font-size:11pt">después de la hora a la que normalmente toma</span><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span><span style="font-family:Times New Roman; font-size:11pt">, no tome la dosis olvidada. Espere y tome la siguiente dosis, con alimentos, a la hora habitual.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si vomita antes de que transcurran 4</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">horas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">tras haber tomado Odefsey</span></strong><span style="font-family:Times New Roman; font-size:11pt">, tome otro comprimido con alimentos.</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Si vomita más de 4</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">horas después de tomar Odefsey</span></strong><span style="font-family:Times New Roman; font-size:11pt">no necesita tomar otro comprimido hasta el siguiente comprimido programado de forma habitual.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con Odefsey</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No interrumpa el tratamiento con Odefsey</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">sin hablar antes con su médico.</span></strong><span style="font-family:Times New Roman; font-size:11pt">Interrumpir la toma de</span><a name="OLE_LINK7" id="OLE_LINK7"><span style="font-family:Times New Roman; font-size:11pt">Odefsey</span></a><span style="font-family:Times New Roman; font-size:11pt">puede afectar gravemente a su respuesta a tratamientos futuros. Si se interrumpe Odefsey por algún motivo, consulte con su médico antes de reiniciar la toma de comprimidos de Odefsey.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cuando vea que le queda poca cantidad de Odefsey</span></strong><span style="font-family:Times New Roman; font-size:11pt">, acuda a su médico o farmacéutico para que le proporcione más. Esto es muy importante, ya que la cantidad de virus puede empezar a aumentar si el medicamento se interrumpe incluso durante un corto periodo de tiempo. Es posible que entonces la enfermedad se vuelva más difícil de tratar.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene tanto una infección por VIH como hepatitis</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">B,</span></strong><span style="font-family:Times New Roman; font-size:11pt">es especialmente importante no suspender su tratamiento con Odefsey sin antes hablar con su médico. Puede necesitar hacerse análisis de sangre durante varios meses tras suspender el tratamiento. En algunos pacientes con enfermedad hepática avanzada o cirrosis, no se recomienda suspender el tratamiento ya que esto puede producir un empeoramiento de su hepatitis, situación que puede ser potencialmente mortal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Hable con su médico</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">inmediatamente</span></strong><span style="font-family:Times New Roman; font-size:11pt">acerca de síntomas nuevos o inusuales tras suspender su tratamiento, particularmente síntomas que asocie con la infección por el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico o farmacéutico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="fadeafd9-27e9-448a-b144-8ce293e6c9d8"><title value="4. Posibles efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029910" /><display value="Posibles efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Posibles efectos adversos: informe a un médico inmediatamente</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cualquier signo de inflamación o infección</span></strong><span style="font-family:Times New Roman; font-size:11pt">. En algunos pacientes con infección avanzada por el VIH (SIDA) y antecedentes de infecciones oportunistas (infecciones que ocurren en personas con un sistema inmunitario débil), se pueden producir signos y síntomas de inflamación por infecciones previas poco después de iniciar el tratamiento contra el VIH. Se cree que estos síntomas se deben a una mejoría de la respuesta inmunitaria del organismo, que le permite combatir infecciones que podrían haber estado presentes sin síntomas obvios.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se pueden producir también</span><strong><span style="font-family:Times New Roman; font-size:11pt;">trastornos autoinmunitarios</span></strong><span style="font-family:Times New Roman; font-size:11pt">, en los que el sistema inmunitario ataca a los tejidos sanos del organismo, después de que empiece a tomar medicamentos para la infección por el VIH. Los trastornos autoinmunitarios se pueden producir muchos meses después del inicio del tratamiento. Esté atento a cualquier síntoma de infección u otros síntomas, como:</span></li></ul><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">-</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">debilidad muscular</span></p><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">-</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">debilidad que se inicia en las manos y los pies y se desplaza hacia el tronco</span></p><p style="margin:0pt 0pt 0pt 28.35pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">-</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">palpitaciones, temblor o hiperactividad</span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos síntomas o cualquier síntoma de inflamación o infección, informe a su médico inmediatamente.</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos muy frecuentes</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">pueden afectar a más de 1 de cada 10</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">personas</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultad para dormir (</span><em><span style="font-family:Times New Roman; font-size:11pt;">insomnio</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de cabeza</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">mareo</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ganas de vomitar (náuseas)</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Los análisis también pueden mostrar:</span></em></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de los niveles de colesterol y/o amilasa pancreática (una enzima digestiva) en la sangre</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de los niveles de enzimas hepáticas en la sangre</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos frecuentes</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">pueden afectar hasta 1 de cada 10</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">personas</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">disminución del apetito</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">depresión</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sueños anormales</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">trastornos del sueño</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">estado de ánimo deprimido</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sensación de sueño (somnolencia)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cansancio</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de estómago o malestar</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">vomitar (</span><em><span style="font-family:Times New Roman; font-size:11pt;">vómito</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">meteorismos</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sequedad de boca</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">gases (</span><em><span style="font-family:Times New Roman; font-size:11pt;">flatulencia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">diarrea</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">erupción</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Los análisis también pueden mostrar:</span></em></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">baja cantidad de glóbulos blancos (un número de glóbulos blancos reducido puede hacerle más propenso a la infección)</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">baja cantidad de plaquetas (un tipo de célula sanguínea que participa en la coagulación de la</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sangre)</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">disminución de la hemoglobina en la sangre</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de los ácidos grasos (</span><em><span style="font-family:Times New Roman; font-size:11pt;">triglicéridos</span></em><span style="font-family:Times New Roman; font-size:11pt">), bilirrubina o lipasa en la sangre</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos poco frecuentes</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(</span><em><span style="font-family:Times New Roman; font-size:11pt;">pueden afectar hasta 1 de cada 100</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">personas</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">signos o síntomas de inflamación o infección</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">baja cantidad de glóbulos rojos (</span><em><span style="font-family:Times New Roman; font-size:11pt;">anemia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacciones cutáneas graves incluida erupción acompañada por fiebre, hinchazón y problemas hepáticos</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas digestivos que generan molestias después de las comidas</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hinchazón de la cara, labios, lengua o garganta (</span><em><span style="font-family:Times New Roman; font-size:11pt;">angioedema</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">picazón (</span><em><span style="font-family:Times New Roman; font-size:11pt;">prurito</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">habones (</span><em><span style="font-family:Times New Roman; font-size:11pt;">urticaria</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor en las articulaciones (</span><em><span style="font-family:Times New Roman; font-size:11pt;">artralgia</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span></li></ul><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><strong><span style="font-family:Wingdings; font-size:11pt;">?</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">Si considera que alguno de los efectos adversos que sufre es grave, informe a su médico.</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Otros efectos que pueden observarse durante el tratamiento contra el VIH</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La frecuencia de los siguientes efectos adversos no es conocida (la frecuencia no puede estimarse a partir de los datos disponibles).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Problemas óseos</span></strong><span style="font-family:Times New Roman; font-size:11pt">. Algunos pacientes tratados con medicamentos antirretrovirales combinados como Odefsey pueden desarrollar una enfermedad de los huesos llamada</span><em><span style="font-family:Times New Roman; font-size:11pt;">osteonecrosis</span></em><span style="font-family:Times New Roman; font-size:11pt">(muerte del tejido óseo debida a una pérdida del suministro de sangre al hueso). Tomar este tipo de medicamentos durante un tiempo prolongado, tomar corticosteroides, beber alcohol, tener un sistema inmunitario muy débil y tener sobrepeso pueden ser algunos de los muchos factores de riesgo para desarrollar esta enfermedad. Los signos de osteonecrosis son:</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rigidez articular</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">molestias y dolor articular (especialmente de cadera, rodilla y hombro)</span></li><li style="margin:0pt 0pt 0pt 37.01pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultades para moverse</span></li></ul><p style="margin:0pt; text-indent:-14.2pt; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Wingdings; font-size:11pt">?</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Si nota cualquiera de estos síntomas, informe a su médico.</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Durante el tratamiento del VIH puede haber un aumento en el peso y en los niveles de glucosa y lípidos en la sangre. Esto puede estar en parte relacionado con la recuperación de la salud y con el estilo de vida y en el caso de los lípidos en la sangre, algunas veces a los medicamentos para el VIH por sí mismos. Su médico le controlará estos cambios.</span></p></div></text><section id="afb2aced-a52c-4e6d-bc9b-9a9ab8148b2d"><title value="Comunicación de efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029912" /><display value="Comunicación de efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta</span><span style="font-family:Times New Roman; font-size:11pt">cualquier tipo de efecto adverso</span><span style="font-family:Times New Roman; font-size:11pt">, consulte a su médico</span><span style="font-family:Times New Roman; font-size:11pt">o</span><span style="font-family:Times New Roman; font-size:11pt">farmacéutico</span><span style="font-family:Times New Roman; font-size:11pt">,</span><span style="font-family:Times New Roman; font-size:11pt">incluso si se trata de</span><span style="font-family:Times New Roman; font-size:11pt">posibles</span><span style="font-family:Times New Roman; font-size:11pt">efectos</span><span style="font-family:Times New Roman; font-size:11pt">adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través del</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#c0c0c0">sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-family:Times New Roman; font-size:11pt; background-color:#c0c0c0">Apéndice V</span></a><span style="font-family:Times New Roman; font-size:11pt">. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="16b8f3b7-8c16-4d06-bcbc-024656b6f110"><title value="5. Conservación de Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029913" /><display value="Conservación de &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantener este medicamento fuera de la vista y del alcance de los niños.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No utilice este medicamento después de la fecha de caducidad que aparece en la caja y en el frasco después de {CAD}. La fecha de caducidad es el último día del mes que se indica.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservar en el embalaje original para protegerlo de la humedad. Mantener el frasco perfectamente cerrado.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="70126c9e-0552-458b-900f-20bb1c7d10a6"><title value="6. Contenido del envase e información adicional" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029914" /><display value="Contenido del envase e información adicional" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="183285f5-9bef-4747-afdb-fd0081533df6"><title value="Composición de Odefsey" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029915" /><display value="Composición de Odefsey" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Los principios activos son</span></strong><span style="font-family:Times New Roman; font-size:11pt">emtricitabina, rilpivirina y tenofovir alafenamida. Cada comprimido recubierto con película de Odefsey contiene 200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de emtricitabina, rilpivirina hidrocloruro equivalente a 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de rilpivirina y tenofovir alafenamida fumarato equivalente a 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de tenofovir alafenamida.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Los demás componentes son</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Núcleo del comprimido:</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Croscarmelosa sódica, lactosa (en forma de monohidrato), estearato magnésico, celulosa microcristalina, polisorbato 20, povidona.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Cubierta pelicular:</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Macrogol, alcohol polivinílico, talco, dióxido de titanio (E171), óxido de hierro negro (E172).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="505b78e7-8c63-4b84-b785-618bd34ef520"><title value="Aspecto del producto y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029916" /><display value="Aspecto del producto y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Odefsey es un comprimido gris, con forma de cápsula, recubierto con película, marcado en una de las caras con “GSI” y “255” en la otra cara. Odefsey se presenta en frascos de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos y en paquetes de 3 frascos, conteniendo cada uno de ellos 30 comprimidos. Cada frasco contiene un desecante de gel de sílice que debe conservarse en el frasco para ayudar a proteger los comprimidos. El desecante de gel de sílice está contenido en un sobre o recipiente separado, y no se debe tragar.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="65b5be5e-56fe-45e5-9a98-aa10f12efaa6"><title value="Titular de la autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029917" /><display value="Titular de la autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Carrigtohill</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">County Cork, T45 DP77</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Ιrlanda</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Responsable de la fabricación</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">IDA Business and Technology Park</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Carrigtohill</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">County Cork</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Ιrlanda</span></p><p style="margin:0pt; line-height:115%; font-size:11pt; background-color:#ffffff"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Pueden solicitar más información respecto a este medicamento dirigiéndose al representante local del titular de la autoriz</span><span style="font-family:Times New Roman; font-size:11pt">ación de comercialización:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:466.1pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">België/Belgique/Belgien</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Belgium SPRL</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">BVBA</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tél/Tel: + 32 (0) 24 01 35 50</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lietuva</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 48 22 262 8702</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">????????</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">???</span><span style="font-family:Times New Roman; font-size:11pt">.: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Luxembour</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">g</span></strong><span style="font-family:Times New Roman; font-size:11pt">/</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Luxembur</span></strong><span style="font-family:Times New Roman; font-size:11pt">g</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Belgium SPRL</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">BVBA</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tél/Tel: + 32 (0) 24 01 35 50</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ceská</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">republika</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences s.r.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 420 910</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">871</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">986</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Magyarország</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Danmark</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: + 46 (0</span><span style="font-family:Times New Roman; font-size:11pt">) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Malta</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Deutschland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences GmbH</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 49 (0) 89 899890</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Nederland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Netherlands B.V.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 31 (0) 20 718 36 98</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Eesti</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 48 22 262 8702</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Norge</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ελλ?δα</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><a name="OLE_LINK1" id="OLE_LINK1"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ελλ?ς Μ.ΕΠΕ.</span></a></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ: + 30 210 8930 100</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Österreich</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences GesmbH</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 43 1 260 830</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">España</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences, S.L.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 34 91 378 98 30</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Polska</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: + 48 22 262 8702</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">France</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Science</span><span style="font-family:Times New Roman; font-size:11pt">s</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tél: + 33 (0) 1 46 09 41 00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Portugal</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences, Lda.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 351 21 7928790</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hrvatska</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">România</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ireland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 214 825 999</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenija</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ireland UC</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 (0) 1 686 1888</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ísland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sími: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenská</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">republika</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Slovakia s.r.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 421 232</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">121</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">210</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Italia</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences S.r.l.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 39 02 439201</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Suomi</span></strong><span style="font-family:Times New Roman; font-size:11pt">/</span><strong><span style="font-family:Times New Roman; font-size:11pt;">Finland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puh/Tel: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Κ?προς</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ελλ?ς Μ.ΕΠΕ.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ: + 30 210 8930 100</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sverige</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Sweden AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 46 (0) 8 5057 1849</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:232.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Latvija</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Poland Sp. z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 48 22 262 8702</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:233.9pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">United</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">Kingdom</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Gilead Sciences Ltd.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 44 (0) 8000 113 700</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr></table><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="b4cf9537-0252-4f7b-b2f7-9555a634fb74"><title value="" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos:</span><span style="font-family:Times New Roman; font-size:11pt">http://www.ema.europa.eu.</span></p></div></text></section></section></section></Composition></resource></entry></Bundle></resource></entry></Bundle>